1
|
Aramaki S, Tsuge S, Islam A, Eto F, Sakamoto T, Oyama S, Li W, Zhang C, Yamaguchi S, Takatsuka D, Hosokawa Y, Waliullah ASM, Takahashi Y, Kikushima K, Sato T, Koizumi K, Ogura H, Kahyo T, Baba S, Shiiya N, Sugimura H, Nakamura K, Setou M. Lipidomics-based tissue heterogeneity in specimens of luminal breast cancer revealed by clustering analysis of mass spectrometry imaging: A preliminary study. PLoS One 2023; 18:e0283155. [PMID: 37163537 PMCID: PMC10171676 DOI: 10.1371/journal.pone.0283155] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2022] [Accepted: 03/02/2023] [Indexed: 05/12/2023] Open
Abstract
Cancer tissues reflect a greater number of pathological characteristics of cancer compared to cancer cells, so the evaluation of cancer tissues can be effective in determining cancer treatment strategies. Mass spectrometry imaging (MSI) can evaluate cancer tissues and even identify molecules while preserving spatial information. Cluster analysis of cancer tissues' MSI data is currently used to evaluate the phenotype heterogeneity of the tissues. Interestingly, it has been reported that phenotype heterogeneity does not always coincide with genotype heterogeneity in HER2-positive breast cancer. We thus investigated the phenotype heterogeneity of luminal breast cancer, which is generally known to have few gene mutations. As a result, we identified phenotype heterogeneity based on lipidomics in luminal breast cancer tissues. Clusters were composed of phosphatidylcholine (PC), triglycerides (TG), phosphatidylethanolamine, sphingomyelin, and ceramide. It was found that mainly the proportion of PC and TG correlated with the proportion of cancer and stroma on HE images. Furthermore, the number of carbons in these lipid class varied from cluster to cluster. This was consistent with the fact that enzymes that synthesize long-chain fatty acids are increased through cancer metabolism. It was then thought that clusters containing PCs with high carbon counts might reflect high malignancy. These results indicate that lipidomics-based phenotype heterogeneity could potentially be used to classify cancer for which genetic analysis alone is insufficient for classification.
Collapse
Affiliation(s)
- Shuhei Aramaki
- Department of Cellular and Molecular Anatomy, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan
- Department of Radiation Oncology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan
- First Department of Pathology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan
| | - Shogo Tsuge
- Department of Cellular and Molecular Anatomy, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan
| | - Ariful Islam
- Department of Cellular and Molecular Anatomy, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan
| | - Fumihiro Eto
- Department of Cellular and Molecular Anatomy, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan
| | - Takumi Sakamoto
- Department of Cellular and Molecular Anatomy, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan
| | - Soho Oyama
- Department of Cellular and Molecular Anatomy, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan
| | - Wenxin Li
- Department of Radiation Oncology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan
| | - Chi Zhang
- Department of Cellular and Molecular Anatomy, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan
| | - Shinichi Yamaguchi
- Analytical & Measuring Instruments Division, Shimadzu Corporation, Kyoto, Japan
| | - Daiki Takatsuka
- 1st Department of Surgery, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan
| | - Yuko Hosokawa
- 1st Department of Surgery, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan
| | - A S M Waliullah
- Department of Cellular and Molecular Anatomy, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan
| | - Yutaka Takahashi
- Department of Cellular and Molecular Anatomy, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan
| | - Kenji Kikushima
- Department of Cellular and Molecular Anatomy, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan
| | - Tomohito Sato
- Department of Cellular and Molecular Anatomy, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan
- 1st Department of Surgery, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan
- International Mass Imaging Center, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan
| | - Kei Koizumi
- 1st Department of Surgery, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan
| | - Hiroyuki Ogura
- 1st Department of Surgery, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan
| | - Tomoaki Kahyo
- Department of Cellular and Molecular Anatomy, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan
- International Mass Imaging Center, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan
| | - Satoshi Baba
- Department of Diagnostic Pathology, Hamamatsu University School of Medicine, Hamamatsu, Japan
| | - Norihiko Shiiya
- 1st Department of Surgery, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan
| | - Haruhiko Sugimura
- First Department of Pathology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan
| | - Katsumasa Nakamura
- Department of Radiation Oncology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan
| | - Mitsutoshi Setou
- Department of Cellular and Molecular Anatomy, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan
- International Mass Imaging Center, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan
| |
Collapse
|
2
|
Miyaue N, Hosokawa Y, Yamanishi Y, Tada S, Ando R, Nagai M. Clinical use of CSF neopterin levels in CNS demyelinating diseases. J Neurol Sci 2022; 441:120385. [PMID: 36027640 DOI: 10.1016/j.jns.2022.120385] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2022] [Revised: 08/08/2022] [Accepted: 08/15/2022] [Indexed: 10/15/2022]
Abstract
BACKGROUND There is some phenotypic overlap between MS, AQP4-IgG positive NMOSD, and MOG-IgG associated disease (MOGAD), and distinguishing a true relapse and a pseudorelapse can be difficult. CSF neopterin, a marker of inflammation-immune-mediated processes in the CNS, may be a useful marker in a wide range of CNS infectious and inflammatory diseases. We compared CSF neopterin levels and other CSF parameters in patients with MS, AQP4-IgG-positive NMOSD, and MOGAD and also investigated whether CSF neopterin levels can distinguish between active and inactive phases of the diseases. METHODS We retrospectively reviewed the medical records of 22 patients with MS, 18 with AQP4-IgG-positive NMOSD, and five with MOGAD. CSF neopterin concentrations were measured by HPLC with fluorometric detection. RESULTS CSF neopterin levels at diagnosis were significantly higher in patients with AQP4-IgG-positive NMOSD (52.77 ± 34.56 pmol/mL) than patients with MS (16.92 ± 5.03 pmol/mL, p < 0.001), and tended to be higher in patients with MOGAD (28.87 ± 9.66 pmol/mL) than patients with MS (p = 0.092). ROC analysis revealed that CSF neopterin most accurately discriminated between MS and AQP4-IgG-positive NMOSD (AUC, 0.912; sensitivity, 75.0%; specificity, 100.0%). At diagnosis/relapse and during remission, CSF neopterin most accurately discriminated between the disease phases in patients with MS (AUC, 0.779; sensitivity, 58.1%; specificity, 94.7%) and patients with AQP4-IgG-positive NMOSD (AUC, 0.934; sensitivity, 83.3%; specificity, 94.1%). CONCLUSION Measurement of CSF neopterin may be useful for differential diagnosis and assessment of disease activity in CNS demyelinating diseases. Further studies with larger cohorts, including comparisons with other biomarkers, are needed to validate the utility of CSF neopterin.
Collapse
Affiliation(s)
- Noriyuki Miyaue
- Department of Clinical Pharmacology and Therapeutics, Ehime University Graduate School of Medicine, Tohon, Ehime, Japan.
| | - Yuko Hosokawa
- Department of Clinical Pharmacology and Therapeutics, Ehime University Graduate School of Medicine, Tohon, Ehime, Japan
| | - Yuki Yamanishi
- Department of Clinical Pharmacology and Therapeutics, Ehime University Graduate School of Medicine, Tohon, Ehime, Japan
| | - Satoshi Tada
- Department of Clinical Pharmacology and Therapeutics, Ehime University Graduate School of Medicine, Tohon, Ehime, Japan
| | - Rina Ando
- Department of Clinical Pharmacology and Therapeutics, Ehime University Graduate School of Medicine, Tohon, Ehime, Japan
| | - Masahiro Nagai
- Department of Clinical Pharmacology and Therapeutics, Ehime University Graduate School of Medicine, Tohon, Ehime, Japan
| |
Collapse
|
3
|
Miyaue N, Yoshida A, Yamanishi Y, Tada S, Ando R, Hosokawa Y, Yabe H, Nagai M. Refractory Longitudinally Extensive Transverse Myelitis after Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination in a Japanese Man. Intern Med 2022; 61:739-742. [PMID: 34897155 PMCID: PMC8943383 DOI: 10.2169/internalmedicine.8747-21] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been developed and administered worldwide. There have been reports of neurological adverse events following immunization (AEFIs). We herein report a case of refractory longitudinally extensive transverse myelitis in a 75-year-old Japanese man following the first dose of the BNT162b2 vaccine. The patient developed total sensory loss below the umbilicus and complete paralysis in both legs. Although he was treated with steroid therapy and plasma exchange, his recovery was limited, and severe sequelae remained. Further studies, including large epidemiological studies, are required to understand the association between SARS-CoV-2 vaccines and neurological AEFI.
Collapse
Affiliation(s)
- Noriyuki Miyaue
- Department of Clinical Pharmacology and Therapeutics, Ehime University Graduate School of Medicine, Japan
| | - Akira Yoshida
- Department of Clinical Pharmacology and Therapeutics, Ehime University Graduate School of Medicine, Japan
| | - Yuki Yamanishi
- Department of Clinical Pharmacology and Therapeutics, Ehime University Graduate School of Medicine, Japan
| | - Satoshi Tada
- Department of Clinical Pharmacology and Therapeutics, Ehime University Graduate School of Medicine, Japan
| | - Rina Ando
- Department of Clinical Pharmacology and Therapeutics, Ehime University Graduate School of Medicine, Japan
| | - Yuko Hosokawa
- Department of Neurology, Saiseikai Matsuyama Hospital, Japan
| | - Hayato Yabe
- Department of Neurology, Saiseikai Matsuyama Hospital, Japan
| | - Masahiro Nagai
- Department of Clinical Pharmacology and Therapeutics, Ehime University Graduate School of Medicine, Japan
| |
Collapse
|
4
|
Yamanishi Y, Choudhury ME, Yoshida A, Hosokawa Y, Miyaue N, Tada S, Ando R, Murakami S, Miyamoto H, Nagai M. Impact of Intestinal Bacteria on Levodopa Pharmacokinetics in LCIG Therapy. Mov Disord Clin Pract 2022; 9:362-368. [PMID: 35402640 PMCID: PMC8974876 DOI: 10.1002/mdc3.13417] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2021] [Revised: 01/07/2022] [Accepted: 01/21/2022] [Indexed: 11/06/2022] Open
Abstract
Background Levodopa-carbidopa intestinal gel (LCIG) therapy is used in advanced Parkinson's disease (PD) and consists of continuous administration of levodopa directly into the jejunum through a percutaneous endoscopic gastro-jejunal (PEG-J) tube. Recently, the metabolism of levodopa by Enterococcus faecalis (E. faecalis) has been reported. Intestinal bacteria can also affect this therapy. Objectives To investigate intestinal bacteria and examine its impact on levodopa blood concentration in patients with PD receiving LCIG therapy. Methods We enrolled 6 patients receiving LCIG therapy in our department. After PEG-J tube replacement, intestinal bacteria were collected from the tip of the tube and were identified using culture and polymerase chain reaction (PCR) tests. Moreover, the presence of tyrosine decarboxylase, which metabolizes levodopa, was also confirmed by PCR test. The ability of these bacteria to metabolize levodopa was confirmed in vitro. Levodopa blood concentrations were also examined before PEG-J tube replacement. Results Bacteria were detected in all 6 patients. E. faecalis was present in 4 patients. Moreover, tyrosine decarboxylase was detected in 2 patients. The identified bacteria displayed in vitro metabolization to dopamine in the 4 E. faecalis positive samples. The addition of carbidopa did not inhibit the metabolism of levodopa. However, there was no difference in the mean blood concentration of levodopa, regardless of the presence of E. faecalis. Conclusions We found bacteria, including E. faecalis in the PEG-J tube. We observed levodopa metabolism in vitro, but there was no association with levodopa blood concentration. The effect of intestinal bacteria may be limited in patients receiving LCIG therapy.
Collapse
Affiliation(s)
- Yuki Yamanishi
- Department of Clinical Pharmacology and TherapeuticsEhime University Graduate School of MedicineToonJapan
| | | | - Akira Yoshida
- Department of Clinical Pharmacology and TherapeuticsEhime University Graduate School of MedicineToonJapan
| | - Yuko Hosokawa
- Department of Clinical Pharmacology and TherapeuticsEhime University Graduate School of MedicineToonJapan
| | - Noriyuki Miyaue
- Department of Clinical Pharmacology and TherapeuticsEhime University Graduate School of MedicineToonJapan
| | - Satoshi Tada
- Department of Clinical Pharmacology and TherapeuticsEhime University Graduate School of MedicineToonJapan
| | - Rina Ando
- Department of Clinical Pharmacology and TherapeuticsEhime University Graduate School of MedicineToonJapan
| | - Shinobu Murakami
- Department of Clinical LaboratoryEhime University HospitalToonJapan
| | - Hitoshi Miyamoto
- Department of Clinical LaboratoryEhime University HospitalToonJapan
| | - Masahiro Nagai
- Department of Clinical Pharmacology and TherapeuticsEhime University Graduate School of MedicineToonJapan
| |
Collapse
|
5
|
Hosokawa Y, Miyaue N, Yabe H. [Clinical picture of patients with Parkinson's disease attending a regional core hospital in Ehime]. Rinsho Shinkeigaku 2021; 62:1-7. [PMID: 34924468 DOI: 10.5692/clinicalneurol.cn-001653] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
The number of Parkinson's disease (PD) patients has been increasing year by year in Japan. However, there are few reports that comprehensively evaluate the symptoms and treatment details of PD patients. We collected and analyzed information on PD patients regularly visiting the Department of Neurology at Saiseikai Matsuyama Hospital as of the end of October 2020. We included 187 patients (83 males and 104 females) with a mean age of 73.6 years and a mean disease duration of 8.9 years. The disease duration was positively correlated with Hoehn & Yahr (HY) stage and the number of antiparkinsonian drugs. The L-dopa equivalent dose decreased after 20 years of disease duration or HY 5. Wearing-off phenomenon and L-dopa-induced dyskinesia were more common in patients with longer duration of disease and higher daily dose of L-dopa. This study provides an overview of the clinical picture of PD patients in a regional core hospital.
Collapse
Affiliation(s)
- Yuko Hosokawa
- Department of Neurology, Saiseikai Matsuyama Hospital
| | | | - Hayato Yabe
- Department of Neurology, Saiseikai Matsuyama Hospital
| |
Collapse
|
6
|
Hosokawa Y. Challenges when introducing NRFit™ at a tertiary hospital in japan. Int J Obstet Anesth 2021; 49:103244. [PMID: 35012813 DOI: 10.1016/j.ijoa.2021.103244] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/08/2021] [Revised: 09/26/2021] [Accepted: 12/12/2021] [Indexed: 10/19/2022]
Affiliation(s)
- Y Hosokawa
- Department of Anesthesiology, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8555, Japan.
| |
Collapse
|
7
|
Masuda Y, Kumagi T, Miyaue N, Hosokawa Y, Yabe H. The Eldest Female Case of Myasthenia Gravis with an Unusual Presentation: Aspiration Pneumonia as the Initial Manifestation. Cureus 2021; 13:e19268. [PMID: 34900462 PMCID: PMC8648139 DOI: 10.7759/cureus.19268] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/04/2021] [Indexed: 11/05/2022] Open
Abstract
We report the eldest female case of myasthenia gravis (MG) that initially presented with aspiration pneumonia. A 91-year-old female with a high-grade fever and general malaise who had suffered from expectoration for several years was diagnosed with aspiration pneumonia. Thorough medical history taking and physical examination suggested the possibility of MG as a cause of aspiration pneumonia. Positive acetylcholine receptor antibody and waning phenomenon on a nerve conduction study confirmed the diagnosis. Treatment with intravenous immunoglobulin, prednisolone, and pyridostigmine resulted in a rapid improvement. Physicians should always consider the etiology of aspiration pneumonia to prevent further negative events.
Collapse
Affiliation(s)
- Yuya Masuda
- Postgraduate Medical Education Center, Ehime University Hospital, Toon, JPN.,Postgraduate Medical Education Center, Saiseikai Matsuyama Hospital, Matsuyama, JPN
| | - Teru Kumagi
- Postgraduate Medical Education Center, Ehime University Hospital, Toon, JPN
| | | | - Yuko Hosokawa
- Neurology, Saiseikai Matsuyama Hospital, Matsuyama, JPN
| | - Hayato Yabe
- Neurology, Saiseikai Matsuyama Hospital, Matsuyama, JPN
| |
Collapse
|
8
|
Miyaue N, Hosokawa Y, Yoshida A, Yamanishi Y, Tada S, Ando R, Yabe H, Nagai M. Fasting state is one of the factors associated with plasma levodopa fluctuations during levodopa‒carbidopa intestinal gel treatment. Parkinsonism Relat Disord 2021; 91:55-58. [PMID: 34509136 DOI: 10.1016/j.parkreldis.2021.09.001] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/17/2021] [Revised: 08/18/2021] [Accepted: 09/05/2021] [Indexed: 11/30/2022]
Abstract
INTRODUCTION Some patients with Parkinson's disease (PD) undergoing levodopa‒carbidopa intestinal gel (LCIG) treatment experience motor fluctuations in the afternoon. The migrating motor complex, a specific periodic migrating contraction pattern occurring in the stomach and small intestine during the fasting state, can affect drug absorption. We aimed to compare the pharmacokinetic parameters between two conditions (with and without lunch) and assessed the influence of the fasting state on the levodopa pharmacokinetics in LCIG treatment. METHODS We evaluated the levodopa pharmacokinetics from 12:00 p.m. to 6:00 p.m. in 10 LCIG-treated PD patients in the presence and absence of lunch. RESULTS The maintenance dose of LCIG correlated strongly with the mean plasma concentration of levodopa in the absence (r = 0.94, coefficient of determination (R2) = 0.89, p < 0.001) or presence of lunch (r = 0.96, R2 = 0.93, p < 0.001). Comparison of the pharmacokinetic parameters revealed that the coefficient of variation was significantly greater in the condition without lunch than in the condition with lunch (p = 0.004): 16.73% (4.88%) without lunch and 9.22% (3.80%) with lunch. There were no significant differences in the mean plasma concentration of levodopa (p = 0.49) and area under the plasma concentration‒time curve (p = 0.27) between the two conditions. CONCLUSIONS Plasma concentrations of levodopa fluctuated more in patients undergoing LCIG treatment without than with lunch. Our results indicate that a small amount of food intake may be a better corrective approach for worsening of symptoms in the fasting state rather than additional levodopa.
Collapse
Affiliation(s)
- Noriyuki Miyaue
- Department of Clinical Pharmacology and Therapeutics, Ehime University Graduate School of Medicine, Tohon, Ehime, Japan; Department of Neurology, Saiseikai Matsuyama Hospital, Matsuyama, Ehime, Japan.
| | - Yuko Hosokawa
- Department of Clinical Pharmacology and Therapeutics, Ehime University Graduate School of Medicine, Tohon, Ehime, Japan
| | - Akira Yoshida
- Department of Clinical Pharmacology and Therapeutics, Ehime University Graduate School of Medicine, Tohon, Ehime, Japan
| | - Yuki Yamanishi
- Department of Clinical Pharmacology and Therapeutics, Ehime University Graduate School of Medicine, Tohon, Ehime, Japan
| | - Satoshi Tada
- Department of Clinical Pharmacology and Therapeutics, Ehime University Graduate School of Medicine, Tohon, Ehime, Japan
| | - Rina Ando
- Department of Clinical Pharmacology and Therapeutics, Ehime University Graduate School of Medicine, Tohon, Ehime, Japan
| | - Hayato Yabe
- Department of Neurology, Saiseikai Matsuyama Hospital, Matsuyama, Ehime, Japan
| | - Masahiro Nagai
- Department of Clinical Pharmacology and Therapeutics, Ehime University Graduate School of Medicine, Tohon, Ehime, Japan
| |
Collapse
|
9
|
Fujii H, Kitazume Y, Uozumi R, Iihara H, Takahashi M, Arai T, Yoshizawa T, Murachi Y, Sato Y, Mikami T, Hashiguchi K, Takahashi K, Fujita Y, Yamazaki T, Hosokawa Y, Morozumi I, Tsuchiya M, Yokoyama A, Hashimoto H, Yamaguchi M. 498P Association between capecitabine efficacy and proton pump inhibitors in patients with stage II-III colorectal cancer: A retrospective multicenter study. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
10
|
Nakashima D, Mori E, Takeda T, Hosokawa Y, Takaishi S, Omura K, Kojima H, Otori N. Preemptive analgesia for endoscopic sinus surgery: a retrospective study. Rhinology 2021; 59:398-401. [PMID: 34185822 DOI: 10.4193/rhin20.624] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
BACKGROUND Chronic rhinosinusitis (CRS) is a common disease, and endoscopic sinus surgery (ESS) is widely performed. However, there is no consensus regarding postoperative pain control after ESS, and postoperative opioid abuse is a problem in many countries. Acetaminophen is reportedly effective for postoperative pain control. Preemptive analgesia has received more attention lately, wherein pain is prevented before it occurs. In this study, we assessed the use of acetaminophen for preemptive analgesia during the perioperative period in ESS. METHODOLOGY This is a retrospective study of 175 patients who underwent ESS, septoplasty, and bilateral inferior turbinate mucosal resection at our hospital from April 2016 to February 2018. In total, 82 patients received 1,000 mg of acetaminophen during surgery and 4 hours after the first dose, while 93 patients did not receive it routinely. We compared these two groups. The primary outcome was the need to use additional analgesics prescribed by the ward physician and the secondary outcomes included postoperative pain, postoperative bleeding, reoperation, blood pressure, and body temperature. RESULTS The use of additional oral and intravenous analgesics was significantly reduced in the patients who received acetaminophen perioperatively. CONCLUSION Preemptive analgesia during the perioperative period of ESS could lead to satisfactory postoperative pain control.
Collapse
Affiliation(s)
- D Nakashima
- Department of Otorhinolaryngology, The Jikei University School of Medicine, Tokyo, Japan
| | - E Mori
- Department of Otorhinolaryngology, The Jikei University School of Medicine, Tokyo, Japan
| | - T Takeda
- Department of Otorhinolaryngology, The Jikei University School of Medicine, Tokyo, Japan
| | - Y Hosokawa
- Department of Otorhinolaryngology, The Jikei University School of Medicine, Tokyo, Japan
| | - S Takaishi
- Department of Otorhinolaryngology, The Jikei University School of Medicine, Tokyo, Japan
| | - K Omura
- Department of Otorhinolaryngology, The Jikei University School of Medicine, Tokyo, Japan
| | - H Kojima
- Department of Otorhinolaryngology, The Jikei University School of Medicine, Tokyo, Japan
| | - N Otori
- Department of Otorhinolaryngology, The Jikei University School of Medicine, Tokyo, Japan
| |
Collapse
|
11
|
Matsuda J, Takano H, Sekine T, Sangen H, Kubota Y, Imori Y, Nakata J, Saiki Y, Miyachi H, Tara S, Hosokawa Y, Tokita Y, Yamamoto T, Kumita S, Shimizu W. P889Clinical significance of four-dimensional flow magnetic resonance imaging measurement of turbulent kinetic energy for hypertrophic obstructive cardiomyopathy. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz747.0486] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Four-dimensional flow magnetic resonance imaging (4D flow MRI) provides the detailed visualization of complex blood flow patterns and the evaluation of energy loss. Turbulent kinetic energy estimation (TKE) is reported to have good correlation with irreversible pressure loss in patients having aortic stenosis or great vessel disease. However, little is known about the usefulness of 4D flow MRI and the significance of TKE value in hypertrophic cardiomyopathy (HCM).
Purpose
The aims of this study were to investigate the relationship between TKE value and echocardiographic findings, clinical symptoms and evaluate the usefulness of 4D flow MRI to distinguish hypertrophic obstructive cardiomyopathy (HOCM) from non-obstructive HCM (HNCM).
Methods
From April 2018 to January 2019, 18 hypertrophic obstructive cardiomyopathy (HOCM) and 14 non-obstructive HCM (HNCM) patients underwent 4D flow MRI. We investigated TKE value calculated by 4D flow MRI, echocardiographic findings; left ventricular pressure gradient (LVPG), mitral regurgitation (MR) and clinical symptom.
Results
HOCM was defined by the 30 mmHg or greater of LVPG (HOCM: 87.7±47.3 mmHg, HNCM; 5.8±7.8 mmHg, p<0.001). TKE value in HOCM patients was significantly higher than HNCM (14.2±4.7 mJ vs. 9.0±4.6 mJ, p<0.001). There was a significant positive linear relationship between TKE value and LVPG (r=0.488, p=0.046). There was no significant relationship between NYHA functional class and TKE value (p=0.47) or LVPG (p=0.11). ROC curve analysis showed that optimal cut off point of TKE value between HOCM and HNCM (sensitivity=95%, specificity=62%, AUC=0.798) was 9.270 mJ. Multiple linear regression showed that there was significant association between severity of MR and combination of TKE (p=0.015) or LVPG (p–=0.012). A representative case demonstrated the significant reduction of TKE value 1 week and 3 months after alcohol septal reduction compared with that obtained before the procedure (Figure)
Conclusion
Our findings suggest that 4D Flow MRI can effectively evaluate the energy dissipation associated with LV outflow tract obstruction and TKE value is useful for identifying HOCM. TKE value also can be the novel parameter of the severity of HOCM.
Collapse
Affiliation(s)
- J Matsuda
- Nippon Medical School, Cardiovascular Intensive Care, Tokyo, Japan
| | - H Takano
- Nippon Medical School, Cardiovasculer medicine, Tokyo, Japan
| | - T Sekine
- Nippon Medical School, Radiology, Tokyo, Japan
| | - H Sangen
- Nippon Medical School, Cardiovascular Intensive Care, Tokyo, Japan
| | - Y Kubota
- Nippon Medical School, Cardiovasculer medicine, Tokyo, Japan
| | - Y Imori
- Nippon Medical School, Cardiovasculer medicine, Tokyo, Japan
| | - J Nakata
- Nippon Medical School, Cardiovascular Intensive Care, Tokyo, Japan
| | - Y Saiki
- Nippon Medical School, Cardiovasculer medicine, Tokyo, Japan
| | - H Miyachi
- Nippon Medical School, Cardiovasculer medicine, Tokyo, Japan
| | - S Tara
- Nippon Medical School, Cardiovascular Intensive Care, Tokyo, Japan
| | - Y Hosokawa
- Nippon Medical School, Cardiovascular Intensive Care, Tokyo, Japan
| | - Y Tokita
- Nippon Medical School, Cardiovasculer medicine, Tokyo, Japan
| | - T Yamamoto
- Nippon Medical School, Cardiovascular Intensive Care, Tokyo, Japan
| | - S Kumita
- Nippon Medical School, Radiology, Tokyo, Japan
| | - W Shimizu
- Nippon Medical School, Cardiovasculer medicine, Tokyo, Japan
| |
Collapse
|
12
|
Hosokawa Y, Yamamoyo T, Tanida A, Matsuda J, Sangen H, Nakata J, Tara S, Shimizu W. P3852Twenty-eight-year temporal trends of treatment strategy and short-term outcomes in patients with high-risk pulmonary embolism: impact of ESC guidelines changes. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz745.0691] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Thrombolysis has been recommended for high-risk pulmonary embolism (PE) in ESC guidelines, used as a reference in Japan. Recently, indication of thrombolysis for acute PE has been limited with recent guideline revision. Little is known regarding trends of treatment strategy and mortality in high-risk PE patients.
Purpose
To clarify temporal trends of treatment strategy and short-term outcomes in high-risk PE patients.
Methods
A retrospective analysis of therapeutic interventions and short-term outcomes was performed for 52 consecutive high-risk PE patients including cardiac arrest. According to timing of ESC guidelines update (2000, 2008 and 2014), patients were divided into four time periods: 1992 to 2000, 2001 to 2008, 2009 to 2014, and 2015 to 2018.
Results
Mean age and proportion of male were not different over the period. Nosocomial case decreased from 100% to 25% (p<0.01). Postoperative cases (relative contraindication for thrombolysis) included 43% of all patients. Cardiac arrest and VA-ECMO use were 42% and 21% of all patients. Any thrombolytic therapy including catheter-directed intervention showed a non-significant decrease trend (92%-87%-71%-44%, p=0.067). Temporary or retrieval IVC filter insertion showed a significant downward trend (36%-80%-54%-22%, p=0.025). The entire study 30-day mortality was 23%. There was no significant difference in 30-day mortality over the periods (14%-27%-14%-44%, p=0.303). However, major bleeding decreased significantly (71%-40%-7%-22%, p=0.004) (Table).
Table 1 1992–2000 (n=14) 2001–2008 (n=15) 2009–2014 (n=14) 2015–2018 (n=9) p Age (years) 54±12 59±17 64±13 65±16 0.224 Male 29% 13% 29% 44% 0.269 Any thrombolytic therapy 92% 87% 71% 44% 0.067 Catheter-directed therapy 86% 87% 71% 0% <0.01 with thrombolytics (92%) (83%) (90%) without thromboloytics (8%) (17%) (10%) Only intravenous thrombolysis 8% 7% 7% 44% 0.038 Temporary/retrieval IVC filter 36% 80% 54% 22% 0.025 ICU stay (days) 15±14 10±18 5±4 8±8 0.206 30-day mortality 14% 27% 14% 44% 0.303 Major bleeding 71% 40% 7% 22% 0.004
Conclusion
The temporal analysis identified a decreased trend in any thrombolytic therapy and IVC filter insertion in high-risk PE. The study also found a decreasing trend in major bleeding.
Collapse
Affiliation(s)
- Y Hosokawa
- Nippon Medical School Hospital, Cardiac and Intensive Care Unit, Tokyo, Japan
| | - T Yamamoyo
- Nippon Medical School Hospital, Cardiac and Intensive Care Unit, Tokyo, Japan
| | - A Tanida
- Nippon Medical School Hospital, Cardiac and Intensive Care Unit, Tokyo, Japan
| | - J Matsuda
- Nippon Medical School Hospital, Cardiac and Intensive Care Unit, Tokyo, Japan
| | - H Sangen
- Nippon Medical School Hospital, Cardiac and Intensive Care Unit, Tokyo, Japan
| | - J Nakata
- Nippon Medical School Hospital, Cardiac and Intensive Care Unit, Tokyo, Japan
| | - S Tara
- Nippon Medical School Hospital, Cardiac and Intensive Care Unit, Tokyo, Japan
| | - W Shimizu
- Nippon Medical School, Department of Cardiology, Tokyo, Japan
| |
Collapse
|
13
|
Matsuda J, Takano H, Imori Y, Tokita Y, Sangen H, Nakamura Y, Kubota Y, Nakata J, Miyachi H, Tara S, Hosokawa Y, Yamamoto T, Takagi G, Asai K, Shimizu W. P3550Relationship between post-procedural right bundle branch block and outcome after alcohol septal ablation for hypertrophic obstructive cardiomyopathy. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy563.p3550] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- J Matsuda
- Nippon Medical School, Cardiovasculer medicine, Tokyo, Japan
| | - H Takano
- Nippon Medical School, Cardiovasculer medicine, Tokyo, Japan
| | - Y Imori
- Nippon Medical School, Cardiovasculer medicine, Tokyo, Japan
| | - Y Tokita
- Nippon Medical School, Cardiovasculer medicine, Tokyo, Japan
| | - H Sangen
- Nippon Medical School, Cardiovasculer medicine, Tokyo, Japan
| | - Y Nakamura
- Nippon Medical School, Cardiovasculer medicine, Tokyo, Japan
| | - Y Kubota
- Nippon Medical School, Cardiovasculer medicine, Tokyo, Japan
| | - J Nakata
- Nippon Medical School, Cardiovasculer medicine, Tokyo, Japan
| | - H Miyachi
- Nippon Medical School, Cardiovasculer medicine, Tokyo, Japan
| | - S Tara
- Nippon Medical School, Cardiovasculer medicine, Tokyo, Japan
| | - Y Hosokawa
- Nippon Medical School, Cardiovasculer medicine, Tokyo, Japan
| | - T Yamamoto
- Nippon Medical School, Cardiovasculer medicine, Tokyo, Japan
| | - G Takagi
- Nippon Medical School, Cardiovasculer medicine, Tokyo, Japan
| | - K Asai
- Nippon Medical School, Cardiovasculer medicine, Tokyo, Japan
| | - W Shimizu
- Nippon Medical School, Cardiovasculer medicine, Tokyo, Japan
| |
Collapse
|
14
|
Kuroki N, Nagao K, Takayama T, Hosokawa Y, Tachibana E, Ashida T, Abe D, Yamamoto T, Takayama M. 2994Impact of extracorporeal membrane oxygenation (ECMO) and intra-aortic balloon pump (IABP) for cardiac arrest. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy563.2994] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- N Kuroki
- Tokyo CCU Network, Scientific Committee, Tokyo, Japan
| | - K Nagao
- Tokyo CCU Network, Scientific Committee, Tokyo, Japan
| | - T Takayama
- Tokyo CCU Network, Scientific Committee, Tokyo, Japan
| | - Y Hosokawa
- Tokyo CCU Network, Scientific Committee, Tokyo, Japan
| | - E Tachibana
- Tokyo CCU Network, Scientific Committee, Tokyo, Japan
| | - T Ashida
- Tokyo CCU Network, Scientific Committee, Tokyo, Japan
| | - D Abe
- Tokyo Metropolitan Bokutoh Hospital, Department of Cardiology, Tokyo, Japan
| | - T Yamamoto
- Tokyo CCU Network, Scientific Committee, Tokyo, Japan
| | - M Takayama
- Tokyo CCU Network, Scientific Committee, Tokyo, Japan
| | | |
Collapse
|
15
|
Yalikun Y, Tanaka N, Hosokawa Y, Iino T, Tanaka Y. Embryonic body culturing in an all-glass microfluidic device with laser-processed 4 μm thick ultra-thin glass sheet filter. Biomed Microdevices 2017; 19:85. [PMID: 28929304 DOI: 10.1007/s10544-017-0227-7] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
Abstract
In this paper, we report the development and demonstration of a method to fabricate an all-glass microfluidic cell culturing device without circulation flow. On-chip microfluidic cell culturing is an indispensable technique for cellular replacement therapies and experimental cell biology. Polydimethylsiloxane (PDMS) have become a popular material for fabricating microfluidic cell culture devices because it is a transparent, biocompatible, deformable, easy-to-mold, and gas-permeable. However, PDMS is also a chemically and physically unstable material. For example, PDMS undergoes aging easily even in room temperature conditions. Therefore, it is difficult to control long term experimental culturing conditions. On the other hand, glass is expected to be stable not only in physically but also chemically even in the presence of organic solvents. However, cell culturing still requires substance exchanges such as gases and nutrients, and so on, which cannot be done in a closed space of a glass device without circulation flow that may influence cell behavior. Thus, we introduce a filter structure with micropores onto a glass device to improve permeability to the cell culture space. Normally, it is extremely difficult to fabricate a filter structure on a normal glass plate by using a conventional fabrication method. Here, we demonstrated a method for fabricating an all-glass microfluidic cell culturing device having filters structure. The function of this all-glass culturing device was confirmed by culturing HeLa, fibroblast and ES cells. Compared with the closed glass devices without a filter structure, the numbers of cells in our device increased and embryonic bodies (EBs) were formed. This method offers a new tool in microfluidic cell culture technology for biological analysis and it expands the field of microfluidic cell culture.
Collapse
Affiliation(s)
- Y Yalikun
- Laboratory for Integrated Biodevice, Quantitative Biology Center, RIKEN, Suita, Osaka, 565-0871, Japan
| | - N Tanaka
- Laboratory for Integrated Biodevice, Quantitative Biology Center, RIKEN, Suita, Osaka, 565-0871, Japan
| | - Y Hosokawa
- Graduate School of Materials Science, Nara Institute of Science and Technology, Ikoma, Nara, 630-0192, Japan
| | - T Iino
- Graduate School of Materials Science, Nara Institute of Science and Technology, Ikoma, Nara, 630-0192, Japan
| | - Y Tanaka
- Laboratory for Integrated Biodevice, Quantitative Biology Center, RIKEN, Suita, Osaka, 565-0871, Japan.
| |
Collapse
|
16
|
Ihara T, Hosokawa Y, Kumazawa K, Ishikawa K, Fujimoto J, Yamamoto M, Muramkami T, Goshima N, Ito E, Watanabe S, Semba K. An in vivo screening system to identify tumorigenic genes. Oncogene 2016; 36:2023-2029. [PMID: 27694896 DOI: 10.1038/onc.2016.351] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2016] [Revised: 08/11/2016] [Accepted: 08/15/2016] [Indexed: 12/26/2022]
Abstract
Screening for oncogenes has mostly been performed by in vitro transformation assays. However, some oncogenes might not exhibit their transforming activities in vitro unless putative essential factors from in vivo microenvironments are adequately supplied. Here, we have developed an in vivo screening system that evaluates the tumorigenicity of target genes. This system uses a retroviral high-efficiency gene transfer technique, a large collection of human cDNA clones corresponding to ~70% of human genes and a luciferase-expressing immortalized mouse mammary epithelial cell line (NMuMG-luc). From 845 genes that were highly expressed in human breast cancer cell lines, we focused on 205 genes encoding membrane proteins and/or kinases as that had the greater possibility of being oncogenes or drug targets. The 205 genes were divided into five subgroups, each containing 34-43 genes, and then introduced them into NMuMG-luc cells. These cells were subcutaneously injected into nude mice and monitored for tumor development by in vivo imaging. Tumors were observed in three subgroups. Using DNA microarray analyses and individual tumorigenic assays, we found that three genes, ADORA2B, PRKACB and LPAR3, were tumorigenic. ADORA2B and LPAR3 encode G-protein-coupled receptors and PRKACB encodes a protein kinase A catalytic subunit. Cells overexpressing ADORA2B, LPAR3 or PRKACB did not show transforming phenotypes in vitro, suggesting that transformation by these genes requires in vivo microenvironments. In addition, several clinical data sets, including one for breast cancer, showed that the expression of these genes correlated with lower overall survival rate.
Collapse
Affiliation(s)
- T Ihara
- Department of Life Science and Medical Bioscience, School of Advanced Science and Engineering, Waseda University, Tokyo, Japan
| | - Y Hosokawa
- Department of Life Science and Medical Bioscience, School of Advanced Science and Engineering, Waseda University, Tokyo, Japan
| | - K Kumazawa
- Department of Life Science and Medical Bioscience, School of Advanced Science and Engineering, Waseda University, Tokyo, Japan
| | - K Ishikawa
- Japan Biological Informatics Consortium (JBiC), Tokyo, Japan
| | - J Fujimoto
- Japan Biological Informatics Consortium (JBiC), Tokyo, Japan
| | - M Yamamoto
- Department of Life Science and Medical Bioscience, School of Advanced Science and Engineering, Waseda University, Tokyo, Japan
| | - T Muramkami
- Laboratory of Tumor Biology, Faculty of Pharmacy, Takasaki University of Health and Welfare, Takasaki, Japan
| | - N Goshima
- Quantitative Proteomics Team, Molecular Profiling Research Center for Drug Discovery (molprof), National Institute of Advanced Industrial Science and Technology (AIST), Tokyo, Japan.,Division of Transcriptome Analysis, Fukushima, Japan
| | - E Ito
- Division of Gene Expression Analysis, Fukushima, Japan
| | - S Watanabe
- Division of Gene Expression Analysis, Fukushima, Japan
| | - K Semba
- Department of Life Science and Medical Bioscience, School of Advanced Science and Engineering, Waseda University, Tokyo, Japan.,Division of gene function analysis, Translational Research Center, Fukushima Medical University, Fukushima, Japan
| |
Collapse
|
17
|
Hosokawa Y, Tsujino I, Kiyofuji K, Koura T, Shoda T, Horikoshi A, Sawada S. Placement of Two Types of Spiral Z-Stents at the Bronchial Carina for the Treatment of Terminal Lung Cancer – a New Method. J Int Med Res 2016; 34:556-62. [PMID: 17133786 DOI: 10.1177/147323000603400514] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Dumon® Y-stents and Dynamic stents are used to treat carinal stenosis, but their placement severely impairs the expectoration of secretions, making frequent bronchoscopic aspiration necessary. We report here five patients with terminal lung cancer who had stenosis of the lower trachea and main bronchi treated using spiral Z-stents. A long tapered spiral Z-stent was placed in the lower trachea and one main bronchus, and a short straight spiral Z-stent in the contralateral main bronchus. No patients required bronchoscopic aspiration of secretions after stenting. Before stenting, all of the patients were severely dyspnoeic, requiring oxygen and having to sit in the orthopnoeic position. After stenting, the patients' dyspnoea improved, with one patient becoming ambulant without the need for oxygen support. These results suggest that the use of spiral Z-stents in stenosis of the tracheal carina in advanced lung cancer is effective in reducing the need for bronchoscopic aspiration and enhancing quality of life.
Collapse
Affiliation(s)
- Y Hosokawa
- Department of Internal Medicine, Nihon University Nerima Hikarigaoka Hospital, Tokyo, Japan.
| | | | | | | | | | | | | |
Collapse
|
18
|
Ogura H, Yoshizawa N, Ueda S, Hosokawa Y, Matsunuma R, Tochikubo J, Nasu H, Shigekawa T, Takeuchi H, Osaki A, Saeki T, Yoshimoto K, Ohmae E, Suzuki T, Ueda Y, Yamashita Y, Sakahara H. Abstract P4-03-06: Near-infrared diffuse optical imaging for early prediction to neoadjuvant chemotherapy in patients with primary breast cancer. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p4-03-06] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Diffuse optical spectroscopic imaging (DOSI) can be exploited as a marker of tumor blood volume quantified by tissue hemoglobin (tHb) concentration. In DOSI, frequent measurement is possible for breast cancer patients because of its non-invasiveness. The tHb concentration determined by DOSI is expected to be a new biomarker for prediction of breast cancer response to neoadjuvant chemotherapy (NAC).
Purpose: Our objective is to determine whether early change of tumor tHb concentration predicts pathological complete response (pCR) to NAC in patients with operable breast cancer.
Methods: In a prospective study, one hundred patients with primary breast cancer were enrolled for primary objective analysis. The regimens of NAC were according to the standard of care. Patients underwent sequential scans using DOSI at baseline, after 1st course and 2nd course of chemotherapy. The mean value of tHb (tHbmean) concentration of the targeted lesion was measured and the percentage change in tHbmean (ΔtHbmean) concentration was calculated. Receiver operating curve analysis demonstrated diagnostic performance of DOSI for predicting a pCR.
Results: In interim analysis, it was regarded as a good outcome that area under the curve (AUC) for ΔtHbmean after 1nd course was 0.797 (SE 0.104, 95%CI 0.633-0.911), and after 2st course was 0.867 (SE 0.06, 95%CI 0.715-0.956).
Conclusion: DOSI could predict accurately a pCR to neoadjuvant chemotherapy in patients with primary breast cancer.
Citation Format: Ogura H, Yoshizawa N, Ueda S, Hosokawa Y, Matsunuma R, Tochikubo J, Nasu H, Shigekawa T, Takeuchi H, Osaki A, Saeki T, Yoshimoto K, Ohmae E, Suzuki T, Ueda Y, Yamashita Y, Sakahara H. Near-infrared diffuse optical imaging for early prediction to neoadjuvant chemotherapy in patients with primary breast cancer. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P4-03-06.
Collapse
Affiliation(s)
- H Ogura
- Breast Surgery, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Radiology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Breast Oncology, International Medical Center, Saitama Medical University, Hidaka, Saitama, Japan; Breast Oncology, Saitama Medical University, Iruma, Saitama, Japan; Hamamatsu Photonics K.K., Hamamatsu, Shizuoka, Japan
| | - N Yoshizawa
- Breast Surgery, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Radiology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Breast Oncology, International Medical Center, Saitama Medical University, Hidaka, Saitama, Japan; Breast Oncology, Saitama Medical University, Iruma, Saitama, Japan; Hamamatsu Photonics K.K., Hamamatsu, Shizuoka, Japan
| | - S Ueda
- Breast Surgery, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Radiology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Breast Oncology, International Medical Center, Saitama Medical University, Hidaka, Saitama, Japan; Breast Oncology, Saitama Medical University, Iruma, Saitama, Japan; Hamamatsu Photonics K.K., Hamamatsu, Shizuoka, Japan
| | - Y Hosokawa
- Breast Surgery, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Radiology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Breast Oncology, International Medical Center, Saitama Medical University, Hidaka, Saitama, Japan; Breast Oncology, Saitama Medical University, Iruma, Saitama, Japan; Hamamatsu Photonics K.K., Hamamatsu, Shizuoka, Japan
| | - R Matsunuma
- Breast Surgery, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Radiology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Breast Oncology, International Medical Center, Saitama Medical University, Hidaka, Saitama, Japan; Breast Oncology, Saitama Medical University, Iruma, Saitama, Japan; Hamamatsu Photonics K.K., Hamamatsu, Shizuoka, Japan
| | - J Tochikubo
- Breast Surgery, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Radiology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Breast Oncology, International Medical Center, Saitama Medical University, Hidaka, Saitama, Japan; Breast Oncology, Saitama Medical University, Iruma, Saitama, Japan; Hamamatsu Photonics K.K., Hamamatsu, Shizuoka, Japan
| | - H Nasu
- Breast Surgery, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Radiology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Breast Oncology, International Medical Center, Saitama Medical University, Hidaka, Saitama, Japan; Breast Oncology, Saitama Medical University, Iruma, Saitama, Japan; Hamamatsu Photonics K.K., Hamamatsu, Shizuoka, Japan
| | - T Shigekawa
- Breast Surgery, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Radiology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Breast Oncology, International Medical Center, Saitama Medical University, Hidaka, Saitama, Japan; Breast Oncology, Saitama Medical University, Iruma, Saitama, Japan; Hamamatsu Photonics K.K., Hamamatsu, Shizuoka, Japan
| | - H Takeuchi
- Breast Surgery, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Radiology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Breast Oncology, International Medical Center, Saitama Medical University, Hidaka, Saitama, Japan; Breast Oncology, Saitama Medical University, Iruma, Saitama, Japan; Hamamatsu Photonics K.K., Hamamatsu, Shizuoka, Japan
| | - A Osaki
- Breast Surgery, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Radiology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Breast Oncology, International Medical Center, Saitama Medical University, Hidaka, Saitama, Japan; Breast Oncology, Saitama Medical University, Iruma, Saitama, Japan; Hamamatsu Photonics K.K., Hamamatsu, Shizuoka, Japan
| | - T Saeki
- Breast Surgery, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Radiology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Breast Oncology, International Medical Center, Saitama Medical University, Hidaka, Saitama, Japan; Breast Oncology, Saitama Medical University, Iruma, Saitama, Japan; Hamamatsu Photonics K.K., Hamamatsu, Shizuoka, Japan
| | - K Yoshimoto
- Breast Surgery, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Radiology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Breast Oncology, International Medical Center, Saitama Medical University, Hidaka, Saitama, Japan; Breast Oncology, Saitama Medical University, Iruma, Saitama, Japan; Hamamatsu Photonics K.K., Hamamatsu, Shizuoka, Japan
| | - E Ohmae
- Breast Surgery, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Radiology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Breast Oncology, International Medical Center, Saitama Medical University, Hidaka, Saitama, Japan; Breast Oncology, Saitama Medical University, Iruma, Saitama, Japan; Hamamatsu Photonics K.K., Hamamatsu, Shizuoka, Japan
| | - T Suzuki
- Breast Surgery, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Radiology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Breast Oncology, International Medical Center, Saitama Medical University, Hidaka, Saitama, Japan; Breast Oncology, Saitama Medical University, Iruma, Saitama, Japan; Hamamatsu Photonics K.K., Hamamatsu, Shizuoka, Japan
| | - Y Ueda
- Breast Surgery, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Radiology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Breast Oncology, International Medical Center, Saitama Medical University, Hidaka, Saitama, Japan; Breast Oncology, Saitama Medical University, Iruma, Saitama, Japan; Hamamatsu Photonics K.K., Hamamatsu, Shizuoka, Japan
| | - Y Yamashita
- Breast Surgery, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Radiology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Breast Oncology, International Medical Center, Saitama Medical University, Hidaka, Saitama, Japan; Breast Oncology, Saitama Medical University, Iruma, Saitama, Japan; Hamamatsu Photonics K.K., Hamamatsu, Shizuoka, Japan
| | - H Sakahara
- Breast Surgery, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Radiology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Breast Oncology, International Medical Center, Saitama Medical University, Hidaka, Saitama, Japan; Breast Oncology, Saitama Medical University, Iruma, Saitama, Japan; Hamamatsu Photonics K.K., Hamamatsu, Shizuoka, Japan
| |
Collapse
|
19
|
Taki Y, Ide Y, Tajima S, Hosokawa Y, Matsunuma R, Terada T, Waki M, Ogura H, Shiiya N. A case of Miller Fisher syndrome during preoperative chemotherapy for breast cancer. Int J Clin Exp Med 2015; 8:16914-16917. [PMID: 26629243 PMCID: PMC4659131] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2015] [Accepted: 09/10/2015] [Indexed: 06/05/2023]
Abstract
A 53-year-old woman with breast cancer received FEC treatment (5FU: 500 mg/m(2), epirubicin: 100 mg/m(2), and cyclophosphamide: 500 mg/m(2)) every 3 weeks as preoperative chemotherapy. Fifteen days after her third cycle of FEC, she developed a cold. Diplopia occurred 4 days after developing the cold, and progressive paresthesia of the hands and weakness of the limbs occurred. She had ophthalmoplegia, ataxia, and are flexia and was diagnosed with Miller Fisher Syndrome (MFS). The cause of MFS during chemotherapy is believed to be caused by an immunological response to infection, or drug neurotoxicity. In our case, since the patient underwent an antecedent upper respiratory infection in the period of myelosuppression, her MFS was probably induced by the immunoreaction associated with this infection. Our patient underwent intravenous immunoglobulin therapy. After initiation of the treatment, her neurological symptoms improved, then, she received a fourth cycle of FEC and her remaining neurological symptoms did not worsen. Thus, we report a rare case of MFS developed in immunosuppression by chemotherapy and remind physicians of the alarming triad of MFS symptoms.
Collapse
Affiliation(s)
- Yumiko Taki
- Department of Breast Surgery, Hamamatsu University School of MedicineShizuoka, Japan
| | - Yoshimi Ide
- Department of Breast Surgery, Hamamatsu University School of MedicineShizuoka, Japan
| | - Shogo Tajima
- Department of Pathology, Shizuoka Saiseikai General HospitalShizuoka, Japan
| | - Yuko Hosokawa
- Department of Breast Surgery, Hamamatsu University School of MedicineShizuoka, Japan
| | - Ryoichi Matsunuma
- Department of Breast Surgery, Hamamatsu University School of MedicineShizuoka, Japan
| | - Tatsuhiro Terada
- Department of Neurology, Hamamatsu University School of MedicineShizuoka, Japan
| | - Michihiko Waki
- Department of Cell Biology and Anatomy, Hamamatsu University School of MedicineShizuoka, Japan
| | - Hiroyuki Ogura
- Department of Breast Surgery, Hamamatsu University School of MedicineShizuoka, Japan
| | - Norihiko Shiiya
- Department of Breast Surgery, Hamamatsu University School of MedicineShizuoka, Japan
| |
Collapse
|
20
|
Yorifuji T, Matsubara K, Sakakibara A, Hashimoto Y, Kawakita R, Hosokawa Y, Fujimaru R, Murakami A, Tamagawa N, Hatake K, Nagasaka H, Suzuki J, Urakami T, Izawa M, Kagami M. Abnormalities in chromosome 6q24 as a cause of early-onset, non-obese, non-autoimmune diabetes mellitus without history of neonatal diabetes. Diabet Med 2015; 32:963-7. [PMID: 25809823 DOI: 10.1111/dme.12758] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 03/20/2015] [Indexed: 01/30/2023]
Abstract
AIMS Abnormalities in the imprinted locus on chromosome 6q24 are the most common causes of transient neonatal diabetes mellitus (6q24-related transient neonatal diabetes). 6q24-Related transient neonatal diabetes is characterized by the patient being small-for-gestational age, diabetes mellitus at birth, spontaneous remission within the first few months and frequent recurrence of diabetes after childhood. However, it is not clear whether individuals with 6q24 abnormalities invariably develop transient neonatal diabetes. This study explored the possibility that 6q24 abnormalities might cause early-onset, non-autoimmune diabetes without transient neonatal diabetes. METHODS The 6q24 imprinted locus was screened for abnormalities in 113 Japanese patients with early-onset, non-obese, non-autoimmune diabetes mellitus who tested negative for mutations in the common maturation-onset diabetes of the young (MODY) genes and without a history of transient neonatal diabetes. Positive patients were further analysed by combined loss of heterozygosity / comparative genomic hybridization analysis and by microsatellite analysis. Detailed clinical data were collected through the medical records of the treating hospitals. RESULTS Three patients with paternal uniparental isodisomy of chromosome 6q24 were identified. None presented with hyperglycaemia in the neonatal period. Characteristically, these patients were born small-for-gestational age, representing 27.2% of the 11 patients whose birth weight standard deviation score (SDS) for gestational age was below -2.0. CONCLUSIONS Abnormalities in the imprinted locus on chromosome 6q24 do not necessarily cause transient neonatal diabetes. Non-penetrant 6q24-related diabetes could be an underestimated cause of early-onset, non-autoimmune diabetes in patients who are not obese and born small-for-gestational age.
Collapse
Affiliation(s)
- T Yorifuji
- Department of Pediatric Endocrinology and Metabolism, Children's Medical Center, Osaka City General Hospital, Osaka, Japan
- Department of Genetic Medicine, Osaka City General Hospital, Osaka, Japan
- Clinical Research Center, Osaka City General Hospital, Osaka, Japan
| | - K Matsubara
- Department of Molecular Endocrinology, National Research Institute for Child Health and Development, Tokyo, Japan
| | - A Sakakibara
- Department of Pediatric Endocrinology and Metabolism, Children's Medical Center, Osaka City General Hospital, Osaka, Japan
| | - Y Hashimoto
- Department of Pediatric Endocrinology and Metabolism, Children's Medical Center, Osaka City General Hospital, Osaka, Japan
| | - R Kawakita
- Department of Pediatric Endocrinology and Metabolism, Children's Medical Center, Osaka City General Hospital, Osaka, Japan
| | - Y Hosokawa
- Department of Pediatric Endocrinology and Metabolism, Children's Medical Center, Osaka City General Hospital, Osaka, Japan
| | - R Fujimaru
- Department of Pediatric Endocrinology and Metabolism, Children's Medical Center, Osaka City General Hospital, Osaka, Japan
| | - A Murakami
- Department of Genetic Medicine, Osaka City General Hospital, Osaka, Japan
| | - N Tamagawa
- Department of Genetic Medicine, Osaka City General Hospital, Osaka, Japan
| | - K Hatake
- Clinical Research Center, Osaka City General Hospital, Osaka, Japan
| | - H Nagasaka
- Department of Pediatrics, Takarazuka City Hospital, Japan
| | - J Suzuki
- Department of Pediatrics, Nihon University School of Medicine, Japan
| | - T Urakami
- Department of Pediatrics, Nihon University School of Medicine, Japan
| | - M Izawa
- Department of Endocrinology and Metabolism, Aichi Children's Health and Medical Center, Japan
| | - M Kagami
- Department of Molecular Endocrinology, National Research Institute for Child Health and Development, Tokyo, Japan
| |
Collapse
|
21
|
Ide Y, Waki M, Ishizaki I, Nagata Y, Taki Y, Hosokawa Y, Matsunuma R, Ogura H, Shiiya N, Sanada N, Setou M. Abstract P6-07-05: Single-cell TOF-SIMS reveals that human breast cancer stem cells have significantly lower content of palmitoleic acid compared to their counterpart non-stem cancer cells. Cancer Res 2015. [DOI: 10.1158/1538-7445.sabcs14-p6-07-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
Distinguishing individual cancers according to their biochemical heterogeneity have provided much useful information to clinical site. Recently, the cancer stem cell (CSC) theory has been accepted as a concept that explains the mechanism of cancer recurrence and resistance to treatment. To characterize such particular cell populations in heterogeneous tissues, we conducted combination of fluorescence activated cell sorting (FACS) and time-of-flight secondary-ion mass spectrometry (TOF-SIMS) and applied the method to analyses of breast CSCs. TOF-SIMS, which enables to visualize the composition of molecules with mass over 100 Da that were obtained in specimen, has been employed to analyze surface of industrial materials and biomaterials. This method is thus suitable for performing single cell analysis of membranous lipids.
Methods
Breast cancer specimens surgically resected from two patients were enzymatically dispersed into cells. They were labeled with fluorescence-conjugated antibodies of CD45, CD44, and CD24. The cells of CD45-CD44+ CD24- were sorted as CSCs with FACS as well as CD45-CD44- CD24+ cells as non-stem cancer cells (NSCCs). TOF-SIMS analysis and fatty acid analysis was performed according to our previous study published in Surface and Interface Analysis (1). The surface of the sorted cells was analyzed by a PHI TRIFT V (ULVAC-PHI Inc., Kanagawa, Japan) TOF-SIMS instrument. Primary ion beam is irradiated to the surface of the samples and, secondary ions derived from samples are calculated by time-of-flight with the information of the place where the molecular ions were ejected. Negative secondary ions were obtained with a mass range of m/z 0–1850. Mass spectra were analyzed by WinCadenceN software (ULVAC-PHI Inc.) to obtain ion counts and ion images. Integrated ion intensities of FA were normalized using phosphoric acid intensity. The Welch’s t-test was used to compare the normalized ion counts with P-value < 0.05 taken as statistically significant.
Results
FACS analyses successfully collected CD45-/CD44+/CD24- CSCs and CD45-/CD44-/CD24+ non-stem cancer cells (NSCCs) in both two cases, which were corresponding to o.33% and 0.74% of all cells in case 1, and 0.14% and 1.14% in case 2. TOF-SIMS analyses visualized phosphoric acids and four fatty acid (FA) species in the sorted CSCs and NSCCs. These ions probably came from membranous phosphopolipids and they were uniformly detected from the locus where the cell attached. Integrated ion intensity of palmitoleic acids [FA(16:1)] of CSCs normalized by phosphoric acids signals were significantly decreased than that of CD45-/CD44-/CD24+ NSCCs as a counterpart. Therefore, our novel method successfully provided lipid composition analysis of individual cells classified with complicated combination of marker expressions in clinical specimens composed of heterogeneous cellular populations, and characterized lipid composition of CSCs.
Reference
1. Nagata Y, Ishizaki I, Waki M, Ide Y, Hossen A, Ohnishi K, et al. Glutaraldehyde Fixation Method for Single-Cell Lipid Analysis by Time-of-Flight Secondary Ion-Mass Spectrometry. Surface and interface analysis : SIA. 2014:DOI: 10.1002/sia/5522.
Citation Format: Yoshimi Ide, Michihiko Waki, Itsuko Ishizaki, Yasuyuki Nagata, Yumiko Taki, Yuko Hosokawa, Ryoichi Matsunuma, Hiroyuki Ogura, Norihiko Shiiya, Noriaki Sanada, Mitsutoshi Setou. Single-cell TOF-SIMS reveals that human breast cancer stem cells have significantly lower content of palmitoleic acid compared to their counterpart non-stem cancer cells [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr P6-07-05.
Collapse
Affiliation(s)
- Yoshimi Ide
- 1Hamamatsu University School of Medicine
- 2Hamamatsu University School of Medicine
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Ono T, Ota A, Ito K, Nakaoka T, Karnan S, Konishi H, Furuhashi A, Hayashi T, Yamada Y, Hosokawa Y, Kazaoka Y. Plumbagin suppresses tumor cell growth in oral squamous cell carcinoma cell lines. Oral Dis 2015; 21:501-11. [PMID: 25580997 DOI: 10.1111/odi.12310] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2014] [Revised: 12/13/2014] [Accepted: 12/22/2014] [Indexed: 12/15/2022]
Abstract
OBJECTIVES Plumbagin (PL), a naturally occurring quinoid, exerts antitumoral effects in diverse types of cancer cells. However, the effect of PL on tumor cell proliferation in oral squamous cell carcinoma (OSCC) remains poorly understood. In this study, we assessed the efficacy of PL, in human OSCC cells. METHODS The effect of PL on the cell growth and apoptosis of OSCC cell lines was evaluated using MTT and Annexin V assays, respectively. The effect of PL on mitochondrial membrane potential loss and reactive oxygen species (ROS) generation was evaluated using flow cytometry analysis. RESULTS MTT assay showed that PL dose-dependently suppressed OSCC cell growth, with IC50 values ranging from 3.87 to 14.6 μM. Flow cytometry analysis revealed that PL treatment resulted in a significant decrease in mitochondrial membrane potential and an increase in the number of apoptotic cells. Notably, ROS generation was significantly elevated after PL treatment. Furthermore, a ROS scavenger, N-acetylcysteine (NAC), clearly suppressed the decrease in mitochondrial membrane potential, increase of caspase-3/7 activity, and apoptosis after PL treatment. CONCLUSION This study provides the considerable evidence of the tumor-suppressive effect of PL, thereby highlighting its therapeutic potential for OSCC treatment.
Collapse
Affiliation(s)
- T Ono
- Department of Oral and Maxillofacial Surgery, Aichi Medical University Hospital, Nagakute, Japan
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Kawakita R, Hosokawa Y, Fujimaru R, Tamagawa N, Urakami T, Takasawa K, Moriya K, Mizuno H, Maruo Y, Takuwa M, Nagasaka H, Nishi Y, Yamamoto Y, Aizu K, Yorifuji T. Molecular and clinical characterization of glucokinase maturity-onset diabetes of the young (GCK-MODY) in Japanese patients. Diabet Med 2014; 31:1357-62. [PMID: 24804978 DOI: 10.1111/dme.12487] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/09/2013] [Revised: 03/03/2014] [Accepted: 04/28/2014] [Indexed: 01/04/2023]
Abstract
AIMS To investigate the molecular and clinical characteristics of the largest series of Japanese patients with glucokinase maturity-onset diabetes of the young (GCK-MODY), and to find any features specific to Asian people. METHODS We enrolled 78 Japanese patients with GCK-MODY from 41 families (55 probands diagnosed at the age of 0-14 years and their 23 adult family members). Mutations were identified by direct sequencing or multiplex ligation-dependent probe amplification of all exons of the GCK gene. Detailed clinical and laboratory data were collected on the probands using questionnaires, which were sent to the treating physicians. Data on current clinical status and HbA1c levels were also collected from adult patients. RESULTS A total of 35 different mutations were identified, of which seven were novel. Fasting blood glucose and HbA1c levels of the probands were ≤9.3 mmol/l and ≤56 mmol/mol (7.3%), respectively, and there was considerable variation in their BMI percentiles (0.4-96.2). In total, 25% of the probands had elevated homeostatic assessment of insulin resistance values, and 58.3% of these had evidence of concomitant Type 2 diabetes in their family. The HbA1c levels for adults were slightly higher, up to 61 mmol/mol (7.8%). The incidence of microvascular complications was low. Out of these 78 people with GCK-MODY and 40 additional family members with hyperglycaemia whose genetic status was unknown, only one had diabetic nephropathy. CONCLUSIONS The molecular and clinical features of GCK-MODY in Japanese people are similar to those of other ethnic populations; however, making a diagnosis of GCK-MODY was more challenging in patients with signs of insulin resistance.
Collapse
Affiliation(s)
- R Kawakita
- Department of Pediatric Endocrinology and Metabolism, Children's Medical Center, Osaka, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Nakanishi T, Mukai K, Hosokawa Y, Takegawa D, Matsuo T. Catechins inhibit vascular endothelial growth factor production and cyclooxygenase-2 expression in human dental pulp cells. Int Endod J 2014; 48:277-82. [PMID: 24847951 DOI: 10.1111/iej.12312] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2013] [Accepted: 05/18/2014] [Indexed: 01/08/2023]
Abstract
AIM To investigate the effect of catechins on vascular endothelial growth factor (VEGF) production and cyclooxygenase-2 (COX-2) expression in human dental pulp cells (HDPC) stimulated with bacteria-derived factors or pro-inflammatory cytokines. METHODOLOGY Morphologically fibroblastic cells established from explant cultures of healthy human dental pulp tissues were used as HDPC. HDPC pre-treated with catechins, epigallocatechin-3-gallate (EGCG) or epicatechin gallate (ECG), were exposed to lipopolysaccharide (LPS), peptidoglycan (PG), interlukin-1β (IL-1β) or tumour necrosis factor-α (TNF-α). VEGF production was examined by enzyme-linked immunosorbent assay, and COX-2 expression was assessed by immunoblot. RESULTS EGCG and ECG significantly reduced LPS- or PG-mediated VEGF production in the HDPC in a dose-dependent manner. EGCG also prevented IL-1β-mediated VEGF production. Although TNF-α did not enhance VEGF production in the dental pulp cells, treatment of 20 μg mL(-1) of EGCG decreased the level of VEGF. In addition, the catechins attenuated COX-2 expression induced by LPS and IL-1β. CONCLUSIONS The up-regulated VEGF and COX-2 expressions in the HDPC stimulated with these bacteria-derived factors or IL-1β were diminished by the treatment of EGCG and ECG. These findings suggest that the catechins may be beneficial as an anti-inflammatory tool of the treatment for pulpal inflammation.
Collapse
Affiliation(s)
- T Nakanishi
- Department of Conservative Dentistry, Institute of Health Biosciences, The University of Tokushima Graduate School, Tokushima, Japan
| | | | | | | | | |
Collapse
|
25
|
Matsunuma R, Ogura H, Ide Y, Hosokawa Y, Taki Y, Yoshida M, Tokunaga Y, Koizumi K, Sato T, Hozumi Y, Mori H, Miyamoto Y, Watanabe T, Shiiya N. Abstract OT3-2-03: An efficacy and safety trial of preoperative chemo-endocrine therapy in luminal B (HER2-negative) breast cancer: A prospective multi-institutional study. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-ot3-2-03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: The St.Gallen consensus guideline recommends the sequential administration chemotherapy followed by of endocrine therapy as postoperative therapy for the higher risk ER-positive breast cancer patients based on results of a single study (Albain et al, Lancet 2009). In metastatic settings however, several trials conducted in the 1980's demonstrated that tumor response rates were higher when chemotherapy and tamoxifen were concomitantly administered, than when chemotherapy and tamoxifen administered were given sequentially. In the preoperative settings, pathological complete response (pCR) rate can be used a surrogate marker to predict event-free survival or overall survival in Luminal B(HER2-negative) breast cancer. We therefore designed a prospective randomized safety and efficacy trial in order to test a hypothesis that the concomitant administration of an aromatase inhibitor and chemotherapy improves pathological complete response(pCR) rate than chemotherapy alone in the preoperative setting.
Trial design: The trial is a prospective, multi-center, randomized comparison of chemotherapy alone versus concomitant chmo-endocrine therapy evaluating the efficacy in terms of pCR rate and safety in preoperative settings in patients with Luminal B (HER2-negative) breast cancer. 94 patients were to be accrued into this trial.
- arm A (control): 12 cycles of weekly paclitaxel(80mg/m2) followed by 4 cycles of every 3-week AC(Doxorubicine 60mg/m2, Cyclophosphamide 600mg/m2).
- arm B (experimental): The same chermotherapy as arm A and anastrozole in postmenopausal patients or anastrozole+leuprolerine in premenopansal patients.
Eligibility criteria: 1)Female patients with operable and histologically confirmed invasive breast cancer; 2)HER2-negative; 3)Either ER -positive or PgR-positive; 4)Either Ki67-LI> = 14% and NG> = 2 or NG = 3 regardless of Ki67-LI.
Endpoints : Primary endpoint is the pCR rate. Secondary endpoints are the clinical response rate(RECIST), the adverse events(CTC-AE ver.4.0), the breast conserving rate and the health related quality of life.
Statistical Considerations : The pCR rates in the control arm and the experimental arm are expected to be 10% and 25%, respectively. In order to show the superiority of the experimental arm with an alfa error at 5% and beta error at 20%, calculated number of patients needed were 96.
Present Accrual and Target Accrual: As of June 06, 2013, 18 patients were enrolled from 8 institutions.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr OT3-2-03.
Collapse
Affiliation(s)
- R Matsunuma
- Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Seirei Hamamatsu Hospital, Hamamatsu, Japan; Hamamatsu Medical Center, Hamamatsu, Japan; Enshu Hospital, Hamamatsu, Japan; Jichi Medical University Hospital, Shimotsuke, Japan; Hamamatsu Oncology Center, Hamamatsu, Japan
| | - H Ogura
- Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Seirei Hamamatsu Hospital, Hamamatsu, Japan; Hamamatsu Medical Center, Hamamatsu, Japan; Enshu Hospital, Hamamatsu, Japan; Jichi Medical University Hospital, Shimotsuke, Japan; Hamamatsu Oncology Center, Hamamatsu, Japan
| | - Y Ide
- Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Seirei Hamamatsu Hospital, Hamamatsu, Japan; Hamamatsu Medical Center, Hamamatsu, Japan; Enshu Hospital, Hamamatsu, Japan; Jichi Medical University Hospital, Shimotsuke, Japan; Hamamatsu Oncology Center, Hamamatsu, Japan
| | - Y Hosokawa
- Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Seirei Hamamatsu Hospital, Hamamatsu, Japan; Hamamatsu Medical Center, Hamamatsu, Japan; Enshu Hospital, Hamamatsu, Japan; Jichi Medical University Hospital, Shimotsuke, Japan; Hamamatsu Oncology Center, Hamamatsu, Japan
| | - Y Taki
- Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Seirei Hamamatsu Hospital, Hamamatsu, Japan; Hamamatsu Medical Center, Hamamatsu, Japan; Enshu Hospital, Hamamatsu, Japan; Jichi Medical University Hospital, Shimotsuke, Japan; Hamamatsu Oncology Center, Hamamatsu, Japan
| | - M Yoshida
- Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Seirei Hamamatsu Hospital, Hamamatsu, Japan; Hamamatsu Medical Center, Hamamatsu, Japan; Enshu Hospital, Hamamatsu, Japan; Jichi Medical University Hospital, Shimotsuke, Japan; Hamamatsu Oncology Center, Hamamatsu, Japan
| | - Y Tokunaga
- Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Seirei Hamamatsu Hospital, Hamamatsu, Japan; Hamamatsu Medical Center, Hamamatsu, Japan; Enshu Hospital, Hamamatsu, Japan; Jichi Medical University Hospital, Shimotsuke, Japan; Hamamatsu Oncology Center, Hamamatsu, Japan
| | - K Koizumi
- Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Seirei Hamamatsu Hospital, Hamamatsu, Japan; Hamamatsu Medical Center, Hamamatsu, Japan; Enshu Hospital, Hamamatsu, Japan; Jichi Medical University Hospital, Shimotsuke, Japan; Hamamatsu Oncology Center, Hamamatsu, Japan
| | - T Sato
- Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Seirei Hamamatsu Hospital, Hamamatsu, Japan; Hamamatsu Medical Center, Hamamatsu, Japan; Enshu Hospital, Hamamatsu, Japan; Jichi Medical University Hospital, Shimotsuke, Japan; Hamamatsu Oncology Center, Hamamatsu, Japan
| | - Y Hozumi
- Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Seirei Hamamatsu Hospital, Hamamatsu, Japan; Hamamatsu Medical Center, Hamamatsu, Japan; Enshu Hospital, Hamamatsu, Japan; Jichi Medical University Hospital, Shimotsuke, Japan; Hamamatsu Oncology Center, Hamamatsu, Japan
| | - H Mori
- Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Seirei Hamamatsu Hospital, Hamamatsu, Japan; Hamamatsu Medical Center, Hamamatsu, Japan; Enshu Hospital, Hamamatsu, Japan; Jichi Medical University Hospital, Shimotsuke, Japan; Hamamatsu Oncology Center, Hamamatsu, Japan
| | - Y Miyamoto
- Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Seirei Hamamatsu Hospital, Hamamatsu, Japan; Hamamatsu Medical Center, Hamamatsu, Japan; Enshu Hospital, Hamamatsu, Japan; Jichi Medical University Hospital, Shimotsuke, Japan; Hamamatsu Oncology Center, Hamamatsu, Japan
| | - T Watanabe
- Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Seirei Hamamatsu Hospital, Hamamatsu, Japan; Hamamatsu Medical Center, Hamamatsu, Japan; Enshu Hospital, Hamamatsu, Japan; Jichi Medical University Hospital, Shimotsuke, Japan; Hamamatsu Oncology Center, Hamamatsu, Japan
| | - N Shiiya
- Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Seirei Hamamatsu Hospital, Hamamatsu, Japan; Hamamatsu Medical Center, Hamamatsu, Japan; Enshu Hospital, Hamamatsu, Japan; Jichi Medical University Hospital, Shimotsuke, Japan; Hamamatsu Oncology Center, Hamamatsu, Japan
| |
Collapse
|
26
|
Ishii K, Ogino R, Hosokawa Y, Fujioka C, Nakahara R, Okada W, Kawamorita R, Hayashi Y, Nakajima T. A Treatment Planning and Acute Toxicity of Volumetric Modulated Arc Therapy (VMAT) in the Treatment of High-Risk Prostate Cancer With Whole Pelvic Radiation Therapy. Int J Radiat Oncol Biol Phys 2013. [DOI: 10.1016/j.ijrobp.2013.06.946] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
27
|
Hagiyama M, Inoue T, Furuno T, Iino T, Itami S, Nakanishi M, Asada H, Hosokawa Y, Ito A. Increased expression of cell adhesion molecule 1 by mast cells as a cause of enhanced nerve-mast cell interaction in a hapten-induced mouse model of atopic dermatitis. Br J Dermatol 2013; 168:771-8. [PMID: 23106683 DOI: 10.1111/bjd.12108] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
BACKGROUND Neuroimmunological disorders are involved in the pathogenesis of atopic dermatitis (AD), partly through enhanced sensory nerve-skin mast cell interaction. Cell adhesion molecule 1 (CADM1) is a mast-cell adhesion molecule that mediates the adhesion to, and communication with, sympathetic nerves. OBJECTIVES To investigate the role of mast cell CADM1 in the pathogenesis of AD, CADM1 expression levels by comparing between lesional and nonlesional skin mast cells of an AD mouse model, which was developed by repeated application of trinitrochlorobenzene, and to examine, in cocultures, how the alterations in CADM1 detected in lesional mast cells might affect the sensory nerve-mast cell interaction. METHODS AD-like lesional and nonlesional skin mast cells were collected separately by laser capture microdissection. CADM1 expression was examined by reverse transcription-polymerase chain reaction and CADM1 immunohistochemistry. In cocultures, adhesion between dorsal root ganglion (DRG) neurites and IC2 mast cells was analysed by loading a femtosecond laser-induced impulsive force on neurite-attendant IC2 cells, while cellular communication was monitored as the IC2 cellular response ([Ca(2+)]i increase) after nerve-specific stimulant-induced DRG activation. RESULTS AD-like lesional mast cells expressed three-fold more CADM1 transcripts than nonlesional cells. This was supported at the protein level, shown by immunohistochemistry. In coculture, CADM1 overexpression in IC2 cells strengthened DRG neurite-IC2 cell adhesion and doubled the population of IC2 cells responding to DRG activation. A function-blocking anti-CADM1 antibody abolished these effects in a dose-dependent manner. CONCLUSIONS Increased expression of CADM1 in mast cells appeared to be a cause of enhanced sensory nerve-mast cell interaction in a hapten-induced mouse model of AD.
Collapse
Affiliation(s)
- M Hagiyama
- Department of Pathology, Faculty of Medicine, Kinki University, 377-2 Ohno-Higashi, Osaka-Sayama, Osaka 589-8511, Japan
| | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Ide Y, Waki M, Hayasaka T, Nishio T, Morita Y, Tanaka H, Sasaki T, Koizumi K, Matsunuma R, Hosokawa Y, Ogura H, Shiiya N, Setou M. Human breast cancer tissues contain abundant phosphatidylcholine(36∶1) with high stearoyl-CoA desaturase-1 expression. PLoS One 2013; 8:e61204. [PMID: 23613812 PMCID: PMC3629004 DOI: 10.1371/journal.pone.0061204] [Citation(s) in RCA: 91] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2012] [Accepted: 03/06/2013] [Indexed: 01/23/2023] Open
Abstract
Breast cancer is the leading cause of cancer and mortality in women worldwide. Recent studies have argued that there is a close relationship between lipid synthesis and cancer progression because some enzymes related to lipid synthesis are overexpressed in breast cancer tissues. However, lipid distribution in breast cancer tissues has not been investigated. We aimed to visualize phosphatidylcholines (PCs) and lysoPCs (LPCs) in human breast cancer tissues by performing matrix assisted laser desorption/ionization-imaging mass spectrometry (MALDI-IMS), which is a novel technique that enables the visualization of molecules comprehensively. Twenty-nine breast tissue samples were obtained during surgery and subjected to MALDI-IMS analysis. We evaluated the heterogeneity of the distribution of PCs and LPCs on the tissues. Three species [PC(32∶1), PC(34∶1), and PC(36∶1)] of PCs with 1 mono-unsaturated fatty acid chain and 1 saturated fatty acid chain (MUFA-PCs) and one [PC(34∶0)] of PCs with 2 saturated fatty acid chains (SFA-PC) were relatively localized in cancerous areas rather than the rest of the sections (named reference area). In addition, the LPCs did not show any biased distribution. The relative amounts of PC(36∶1) compared to PC(36∶0) and that of PC(36∶1) to LPC(18∶0) were significantly higher in the cancerous areas. The protein expression of stearoyl-CoA desaturase-1 (SCD1), which is a synthetic enzyme of MUFA, showed accumulation in the cancerous areas as observed by the results of immunohistochemical staining. The ratios were further analyzed considering the differences in expressions of the estrogen receptor (ER), human epidermal growth factor receptor 2 (HER2), and Ki67. The ratios of the signal intensity of PC(36∶1) to that of PC(36∶0) was higher in the lesions with positive ER expression. The contribution of SCD1 and other enzymes to the formation of the observed phospholipid composition is discussed.
Collapse
Affiliation(s)
- Yoshimi Ide
- Department of Surgery I, Hamamatsu University School of Medicine, Hamamatsu, Japan
- Department of Cell Biology and Anatomy, Hamamatsu University School of Medicine, Hamamatsu, Japan
| | - Michihiko Waki
- Department of Cell Biology and Anatomy, Hamamatsu University School of Medicine, Hamamatsu, Japan
| | - Takahiro Hayasaka
- Department of Cell Biology and Anatomy, Hamamatsu University School of Medicine, Hamamatsu, Japan
| | - Tomohisa Nishio
- Department of Laboratory Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan
| | - Yoshifumi Morita
- Department of Cell Biology and Anatomy, Hamamatsu University School of Medicine, Hamamatsu, Japan
| | - Hiroki Tanaka
- Department of Cell Biology and Anatomy, Hamamatsu University School of Medicine, Hamamatsu, Japan
| | - Takeshi Sasaki
- Department of Anatomy and Neuroscience, Hamamatsu University School of Medicine, Hamamatsu, Japan
| | - Kei Koizumi
- Department of Surgery I, Hamamatsu University School of Medicine, Hamamatsu, Japan
| | - Ryoichi Matsunuma
- Department of Surgery I, Hamamatsu University School of Medicine, Hamamatsu, Japan
| | - Yuko Hosokawa
- Department of Surgery I, Hamamatsu University School of Medicine, Hamamatsu, Japan
| | - Hiroyuki Ogura
- Department of Surgery I, Hamamatsu University School of Medicine, Hamamatsu, Japan
| | - Norihiko Shiiya
- Department of Surgery I, Hamamatsu University School of Medicine, Hamamatsu, Japan
| | - Mitsutoshi Setou
- Department of Cell Biology and Anatomy, Hamamatsu University School of Medicine, Hamamatsu, Japan
- * E-mail:
| |
Collapse
|
29
|
Ogura H, Yoshimoto K, Nasu H, Hosokawa Y, Matsunuma R, Ide Y, Yamaki E, Yamashita D, Suzuki T, Oda M, Ueda Y, Yamashita Y, Sakahara H. Abstract P4-03-05: The Clinical Trial of New Optical Mammography. Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-p4-03-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Objectives: Optical mammography (O-MMG), which utilizes near-infrared light for the detection of abnormal breast tissue, can be a potentially useful and non-invasive tool for the screening of breast cancer patients. Here we report on the preliminary results of our clinical trial using a time-resolved O-MMG system developed by Hamamatsu Photonics (Hamamatsu, Japan). In our past examination, negative results included cases with mismatch for breast cup because of small breast, lesion outside of cup because of big breast, and bad positioning. So, size and shape of a gantry was improved (3 cup sizes; S, M and L cup). We reported the initial experience of the improved O-MMG systems.
Materials and Methods: In principle, the technique involves sequential irradiation of the breast tissue with a pulsed laser with a wavelength of 760, 800 and, 830nm, which is then detected by the variable capacity gantry at multiple sites after passing through the breast tissue. Measurement time has improved to about 7 minutes (a third of the conventional measurement time). The data are analyzed and tomographic images of the absorption coefficient of the breast are then reconstructed based on our tomographic reconstruction algorithm. Between October 2011 and May 2012, fifteen patients with breast cancer and one patient with fibroadenoma participated in the trial.
Results: In patients with breast cancer, S cup was used for one patient, M cup for 12 patients and L cup for two patients. Five patients after neo-adjuvant chemotherapy were excluded from the analysis. The lesions were depicted as an area of high hemoglobin concentration in 7 of 10 patients with cancer. One lesion of fibroadenoma was also identified as an area of high hemoglobin concentration.
Conclusion: Further examination with our new O-MMG systems will be of interest.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P4-03-05.
Collapse
Affiliation(s)
- H Ogura
- Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Hamamatsu Photonics K.K., Hamamatsu, Shizuoka, Japan
| | - K Yoshimoto
- Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Hamamatsu Photonics K.K., Hamamatsu, Shizuoka, Japan
| | - H Nasu
- Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Hamamatsu Photonics K.K., Hamamatsu, Shizuoka, Japan
| | - Y Hosokawa
- Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Hamamatsu Photonics K.K., Hamamatsu, Shizuoka, Japan
| | - R Matsunuma
- Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Hamamatsu Photonics K.K., Hamamatsu, Shizuoka, Japan
| | - Y Ide
- Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Hamamatsu Photonics K.K., Hamamatsu, Shizuoka, Japan
| | - E Yamaki
- Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Hamamatsu Photonics K.K., Hamamatsu, Shizuoka, Japan
| | - D Yamashita
- Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Hamamatsu Photonics K.K., Hamamatsu, Shizuoka, Japan
| | - T Suzuki
- Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Hamamatsu Photonics K.K., Hamamatsu, Shizuoka, Japan
| | - M Oda
- Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Hamamatsu Photonics K.K., Hamamatsu, Shizuoka, Japan
| | - Y Ueda
- Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Hamamatsu Photonics K.K., Hamamatsu, Shizuoka, Japan
| | - Y Yamashita
- Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Hamamatsu Photonics K.K., Hamamatsu, Shizuoka, Japan
| | - H Sakahara
- Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Hamamatsu Photonics K.K., Hamamatsu, Shizuoka, Japan
| |
Collapse
|
30
|
Hosokawa Y, Okumura K, Terashima S, Sakakura Y. Radiation protective effect of hypoxia-inducible factor-1α (HIF-1α) on human oral squamous cell carcinoma cell lines. Radiat Prot Dosimetry 2012; 152:159-163. [PMID: 22927657 DOI: 10.1093/rpd/ncs215] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
We examined the effects of 5-Gy radiation on the expression of hypoxia-inducible factor-1α (HIF-1α) and the radiosensitivity of five human oral squamous cell carcinoma (OSCC) cell lines (SAS, Ca9-22, TT, BSC-OF and IS-FOM). In all of the cell lines, HIF-1α was expressed in mRNA, and radiation had no influence on gene transcription. The number of apoptotic cells increased 72 h after irradiation in cell lines SAS, Ca9-22 and TT cells, indicating low transcriptional levels of HIF-1α, and the levels of non-cleaved caspase-3, an executioner of apoptosis, and non-cleaved poly (adenosine diphosphate-ribose) polymerase (PARP), a marker of DNA damage early in apoptosis, decreased simultaneously. Conversely, radiation failed to induce apoptosis or to decrease expression of non-cleaved caspase-3 and PARP in cell lines BSC-OF and IS-FOM cells that expressed high levels of HIF-1α. BSC-OF and IS-FOM cells exhibited high migratory capacity. When CoCl(2) was present in the medium, HIF-1α expression increased along with the survival of Ca9-22 cells after radiation exposure. These results suggest that OSCC cells expressing high levels of HIF-1α are resistant to radiation. HIF-1α can be used to control the short-term radiosensitivity of cells.
Collapse
Affiliation(s)
- Y Hosokawa
- Division of Medical Life Sciences, Hirosaki University, 66-1 Hon-cho, Hirosaki, Aomori 0.6-8564, Japan.
| | | | | | | |
Collapse
|
31
|
Ide Y, Nishio T, Hosokawa Y, Matsunuma R, Koizumi K, Ogura H, Shiiya N, Setou M. P4-05-05: Imaging Mass Spectrometry Based Lipid Metabolites Analysis for Breast Cancer. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-p4-05-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Activation of lipid metabolism is an early event of carcinogenesis and a central hallmark of many cancers including breast cancer. Recent findings argue that stearoyl CoA desaturase-1 (SCD1), a key regulator of the fatty acid (FA) composition and the endoplasmic reticulum resident enzyme that converts saturated FA (SFA) into monounsaturated FA (MUFA) is a novel regulator of carcinogenesis. The distinctive lipids composition of membrane in cancer cells and the biological functions of SCD1, however, still remain uncertain. Imaging mass spectrometry (IMS) is a mass spectrometry-based analyzing technique that enables visualization of the individual molecules without requiring antibodies. It allows comprehensive detection of a wide range of biomolecules, such as lipids. We attempted to visualize the localization of lipids in breast cancer by IMS for better understanding of cancer proliferation.
Materials and methods: 13 specimens were obtained from the primary breast cancer patients. All were Japanese woman and aged 41–86 years (mean 61.5y.o.). Only one patient received preoperative systematic therapy. 6 were estrogen receptor (ER) and/or progesterone receptor (PgR) positive and human epidermal growth factor receptor 2 (HER2) negative, 2 were ER and/or PgR positive and HER2 positive, 2 were both ER and PgR negative and HER2 positive and 2 were triple negative.
IMS: Samples were immediately chilled in liquid Hexan and stored at −80°. All specimens were sliced into 10 mm thin sections, mounted onto one indium-tin oxide-coated glass slides (Bruker Daltonics) and then sprayed by 2,5-Dihydroxybenzoic acid. Matrix assisted laser desorption ionization (MALDI) technique was used as a soft ionization method. We used time of flight (TOF)/TOF type instrument (Ultraflex, Bruker Daltonics) and all the spectrum were acquired automatically using Fleximaging software (Bruker Daltonics). Each spectral intensity at any mass-to-charge ratio (m/z) was measured at 16 regions of interest (ROI); 13 ROI were picked up from cancerous parts and 3 were from non-cancerous parts. Spectral intensities were compared and statistical analysis was performed by Mann Whitney test. The software was also used to create two-dimensional ion-density maps.
Results: In the cancerous parts of all the 13 specimens, two distinct peaks of the molecular ions were detected at m/z 798.5 and 810.5, which were not found in the non-cancerous parts. Median intensity of the molecular ions at m/z 798.5 and 810.5 were 38.9 and 3.18 in the cancerous part, while they were 0.84 and 1.02 in the non-cancerous part (p=0.010 and 0.015, respectively). Tandem mass spectrometry analysis for these two molecules revealed that they were two kinds of phosphatidylcholine (PC), PC (16:0/18:1) and PC (18:0/18:1). Localization of the individual PC was visualized by means of IMS, which showed that in cancerous part accumulation of PCs containing MUFA was more pronounced than those containing SFA only. Conclusion:
Two kinds of PC containing MUFA were found to highly accumulate in cancerous parts, which may suggest involvement of SCD1 in the membrane composition regulation and cancer proliferation. Further studies may thus be warranted to explore the relation between PC localization and the SCD1 expression.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P4-05-05.
Collapse
Affiliation(s)
- Y Ide
- 1Hamamatsu University School of Medicine, Hamamatsu, Japan
| | - T Nishio
- 1Hamamatsu University School of Medicine, Hamamatsu, Japan
| | - Y Hosokawa
- 1Hamamatsu University School of Medicine, Hamamatsu, Japan
| | - R Matsunuma
- 1Hamamatsu University School of Medicine, Hamamatsu, Japan
| | - K Koizumi
- 1Hamamatsu University School of Medicine, Hamamatsu, Japan
| | - H Ogura
- 1Hamamatsu University School of Medicine, Hamamatsu, Japan
| | - N Shiiya
- 1Hamamatsu University School of Medicine, Hamamatsu, Japan
| | - M Setou
- 1Hamamatsu University School of Medicine, Hamamatsu, Japan
| |
Collapse
|
32
|
Ogura H, Yamashita D, Nasu H, Hosokawa Y, Koizumi K, Yamaki E, Yoshimoto K, Suzuki T, Ueda Y, Oda M, Yamashita Y, Sakahara H. OT2-03-03: Spectroscopic Feature of Breast Cancer. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-ot2-03-03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Objectives: To examine optical properties of breast cancer by time-resolved spectroscopy.
Materials and Methods: We irradiated a pulsed laser of 760, 800, and 830 nm wave-length lights at multiple sites of both breasts including the site just above the cancer and detected the light transmitted through the breast with TRS-20SH (Hamamatsu Photonics K.K.). Absorption coefficient (μa), reduced scattering coefficient (μs'), total hemoglobin (tHb), and oxygen saturation (SO2) of the breast were calculated by photon diffusion equation. The clinical trial started in January 2007. A total of one hundred nine breast cancer patients participated in the trial and written informed consent were obtained from all of the patients. Results: In 800 nm wave-length, absorption coefficient (μa) of breast cancer tissue was significantly high, compared with contra-lateral normal breast (cancer:0.0677± 0.0293, normal breast;0.0479± 0.0161, p<0.001).
The result was the same in 760, and 830 nm. There was no difference in reduced scattering coefficient (μs') between breast cancer tissue and contra-lateral normal breast (800 nm cancer:9.070±1.217, normal breast;9.348±1.243, p=0.10). The tHb of breast cancer tissue was significantly high, compared with normal breast (cancer:31.0± 14.7, normal breast;21.0±8.2, p<0.001). There was no difference in oxygen saturation (SO2) between breast cancer tissue and contra-lateral normal breast (cancer:72.8±4.1, normal breast;73.8±4.5, p=0.08).
Conclusion: Absorption coefficient (μa) and tHb increased in breast cancer, whereas reduced scattering coefficient (μs') did not.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr OT2-03-03.
Collapse
Affiliation(s)
- H Ogura
- 1Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Hamamatsu Photonics K.K., Hamamatsu, Shizuoka, Japan
| | - D Yamashita
- 1Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Hamamatsu Photonics K.K., Hamamatsu, Shizuoka, Japan
| | - H Nasu
- 1Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Hamamatsu Photonics K.K., Hamamatsu, Shizuoka, Japan
| | - Y Hosokawa
- 1Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Hamamatsu Photonics K.K., Hamamatsu, Shizuoka, Japan
| | - K Koizumi
- 1Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Hamamatsu Photonics K.K., Hamamatsu, Shizuoka, Japan
| | - E Yamaki
- 1Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Hamamatsu Photonics K.K., Hamamatsu, Shizuoka, Japan
| | - K Yoshimoto
- 1Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Hamamatsu Photonics K.K., Hamamatsu, Shizuoka, Japan
| | - T Suzuki
- 1Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Hamamatsu Photonics K.K., Hamamatsu, Shizuoka, Japan
| | - Y Ueda
- 1Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Hamamatsu Photonics K.K., Hamamatsu, Shizuoka, Japan
| | - M Oda
- 1Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Hamamatsu Photonics K.K., Hamamatsu, Shizuoka, Japan
| | - Y Yamashita
- 1Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Hamamatsu Photonics K.K., Hamamatsu, Shizuoka, Japan
| | - H Sakahara
- 1Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan; Hamamatsu Photonics K.K., Hamamatsu, Shizuoka, Japan
| |
Collapse
|
33
|
Ishihara K, Hosokawa Y, Makita K, Noda J, Ueno H, Muramatsu Y, Ueno H, Mukai T, Yamamoto H, Ito M, Tamura Y. Factors associated with antimicrobial-resistant Escherichia coli in zoo animals. Res Vet Sci 2011; 93:574-80. [PMID: 21975215 DOI: 10.1016/j.rvsc.2011.09.006] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2010] [Revised: 08/30/2011] [Accepted: 09/07/2011] [Indexed: 11/17/2022]
Abstract
Factors associated with the carriage of antimicrobial-resistant Escherichia coli isolates were analysed among zoo animals. An association was observed between selection of amoxicillin as the first-line therapy and a significantly higher percentage of resistance to ampicillin (54.5%) from 11 animals treated with antimicrobials, compared with isolates from 32 untreated animals (9.4%). In addition, the percentage resistance to kanamycin (36.4%), gentamicin (27.3%), trimethoprim (27.3%) and tetracycline (63.6%) from 11 treated animals was significantly higher than those from 32 untreated animals (3.1%, 3.1%, 3.1% and 25%, respectively), although these antimicrobials were rarely used. All kanamycin-, gentamicin- and trimethoprim-resistant isolates and more than half of the tetracycline-resistant isolates from treated animals were also resistant to ampicillin. Co-resistance to other antimicrobials with ampicillin was suggested to contribute to an increasing of resistance towards antimicrobials that were rarely administered. The present investigation revealed an association of antimicrobial treatment with the spread of antimicrobial-resistant bacteria among zoo animals.
Collapse
Affiliation(s)
- Kanako Ishihara
- School of Veterinary Medicine, Rakuno Gakuen University, Ebetsu, Hokkaido, Japan
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Motoori S, Kawase T, Nishimura H, Hosokawa Y, Konno T, Hanai C, Kitagawa N, Saisho H, Furuse J. [Two cases of advanced colorectal cancer which demonstrated the reversibility of oxaliplatin-mediated increase in splenic volume]. Gan To Kagaku Ryoho 2011; 38:677-680. [PMID: 21499004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
Hepatic sinusoidal injury arises occasionally after oxaliplatin-based chemotherapy. As a result, portal hypertension associated with splenomegaly occurs in some cases. We report two cases of advanced colorectal cancer which showed splenomegaly after administration of oxaliplatin-based chemotherapy. In both cases, mFOLFOX6/bevacizumab was administered as a firstline chemotherapy. Splenic volume was determined by loading the CT images onto a commercially available workstation. In case 1, initial splenic volume was 137.82mL. Two months later, it increased to 160.96mL. After six cycles of chemotherapy, we removed oxaliplatin due to peripheral neuropathy. Consequently, the splenic volume decreased to 151.58mL. Subsequent to the reintroduction of oxaliplatin, the splenic volume increased to 177.48mL. Following two cycles of mFOLFOX6/bevacizumab, oxaliplatin was removed again. In a similar way, splenic volume decreased to 158.52mL. In case 2, initial splenic volume was 105.84mL. Ten months later, it increased to 228.54mL. After administration of mFOLFOX6/bevacizumab, we continued chemotherapy with sLV5FU2/bevacizumab and irinotecan. The splenic volume decreased to 197. 06mL. In conclusion, oxaliplatin- based chemotherapy induces an increase in splenic volume, however, it may be reversible after discontinuation of oxaliplatin.
Collapse
Affiliation(s)
- Shigeatsu Motoori
- Dept. of Internal Medicine and Clinical Oncology, Kaken Hospital, Japan
| | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Matsukawa K, Akagi S, Fukunari K, Hosokawa Y, Yonezawa C, Watanebe S, Takahashi S. 52 THE EFFECTS OF DONOR CELL CYCLE AND THE TIMING OF OOCYTE ACTIVATION ON DEVELOPMENT OF BOVINE NUCLEAR TRANSFERRED EMBRYOS IN VIVO. Reprod Fertil Dev 2011. [DOI: 10.1071/rdv23n1ab52] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
The cell cycle of donor cells and recipient cytoplasts are important factors affecting development of nuclear transferred (NT) embryos. We previously showed that bovine NT embryos using pre-activated cytoplasts and early G1 cells had a high in vitro developmental rate (SSR, 2008, 41st Annual Meeting). The objective of the present study was to evaluate the effects of donor cell cycle (early G1 or G0 phase) and the timing of oocyte activation on fetal development of bovine NT embryos. Adult fibroblasts from ear skin tissue of Japanese black cattle were used as donor cells. The G0 phase cells were synchronized by serum-starvation, and the G1 phase cells were prepared from actively dividing M phase cells. NT embryo production was performed by 2 kinds of protocols as follows: 1) recipient oocytes were activated by Ca ionophore (CaI), followed with cycloheximide (CH) for 2 h, and fused with synchronized donor cells followed with cytochalasin D (CD) and CH for 1 h, then CH for 4 h (pre-activated), 2) unactivated oocytes were fused with synchronized donor cells and activation was performed by CaI 1 h after fusion, followed by with CD and CH 1 h, then CH for 4 h (post-activated). After activation treatments, NT embryos were cultured in IVD101 medium for 7 days. Then, blastocysts were transferred to recipient cows. Diagnosis of pregnancy was made by ultrasonography at days 30, 60, and 90 (Day 0 = the day of embryo transfer). As shown in Table 1, the blastocyst formation rate of the NT embryos derived from early G1 cells in the pre-activated group was higher than that from G0 cells in the post-activated group (36% v. 23%, P < 0.05). After embryo transfer, 29, 67, and 50% of recipient cows were pregnant at Day 30 in G0 post-, G1 post-, and G1 pre-activated groups, respectively. However, only 1 embryo (14%) of G0 post-activated group developed to term. In conclusion, bovine NT embryos using early G1 cells and pre-activated cytoplasts showed a high blastocyst formation rate, but the full-term development of bovine NT embryos could not be improved by using early G1 cells and pre-activated cytoplasts.
Table 1.Effect of the timing of oocyte activation on developmental ability of bovine NT embryos derived from early G1 or G0 phase cells
Collapse
|
36
|
Motoori S, Hosokawa Y, Miyazawa T, Iwamoto N, Kase Y, Kitagawa N, Saisho H, Furuse J. [Two cases of colorectal cancer presenting with periodic, transient elevation of serum iron after chemotherapy including irinotecan]. Gan To Kagaku Ryoho 2010; 37:2185-2188. [PMID: 21084824] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
It is known that the serum iron level shows a transient elevation after chemotherapy in some cases; however, the cause of this phenomenon has not been clearly described. We report two cases of colorectal cancer whose serum iron level demonstrated recurrent elevation after administration of irinotecan as a second-line chemotherapy. The transferrin saturation rate showed marked elevation together with serum iron. This fact indicates that the release of non-transferrin bound iron (NTBI) occurs and then, NTBI binds with transferrin immediately thereafter. Additionally, elevation of indirect bilirubin in case 1, and mild anemia in case 2 were observed after every course of chemotherapy. All these phenomena were synchronized with the fluctuation of the serum iron level. These observations suggest that the transient elevation of the serum iron was related with the release of the NTBI from red blood cells after chemotherapy including irinotecan.
Collapse
Affiliation(s)
- Shigeatsu Motoori
- Dept. of Internal Medicine, and Clinical Oncology, Kaken Hospital, Chemotherapy Research Institute
| | | | | | | | | | | | | | | |
Collapse
|
37
|
Hosokawa Y, Motoori S, Miyazawa T, Iwamoto N, Kase Y, Kitagawa N, Saisho H, Furuse J, Itabashi M. [Two cases of colorectal cancer presenting with periodic, transient elevation of serum iron due to hemolysis after chemotherapy including 5-FU]. Gan To Kagaku Ryoho 2010; 37:1805-1808. [PMID: 20841952] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/29/2023]
Abstract
The serum iron level reportedly shows transient elevation after chemotherapy in some cases. However, the cause of this phenomenon has not been clearly described. We report two cases of colorectal cancer whose serum iron level demonstrated recurrent elevation after chemotherapy. Both were advanced colorectal cancer cases with liver metastases, so we started chemotherapy with modified FOLFOX6+bevacizumab. After several courses, we changed the regimen to simplified LV5FU2+ bevacizumab in both cases. The serum iron level showed transient, periodical elevation irrespective of the therapeutic regimen. Additionally, indirect bilirubin also showed transient elevation, which was completely synchronized with the fluctuation of the serum iron level. These observations suggest that hemolysis is the main cause of periodic, transient elevation of serum iron level after chemotherapy including 5-FU.
Collapse
|
38
|
Abstract
BACKGROUND AND OBJECTIVE Because human gingival fibroblasts (HGFs) are the predominant cells in periodontal tissues, we hypothesized that HGFs are contributed to receptors for components of bacteria. In this study, we focused on expression and function of nucleotide binding oligomerization domain 2 (NOD2) in HGFs, which is a mammalian cytosolic pathogen recognition molecule. MATERIAL AND METHODS Expression of NOD2 in HGFs was examined by reverse transcriptase-polymerase chain reaction (RT-PCR) and flow cytometry. Production of interleukin (IL)-6, IL-8, cc chemokine ligand2, cxc chemokine ligand10 (CXCL10) and CXCL11 from HGFs was examined by enzyme-linked immunosorbent assay (ELISA). We used RT-PCR and immunohistochemistry to detect the NOD2 expression in human gingival tissues. RESULTS We found clear NOD2 expression in HGFs. Upon stimulation with NOD2 agonist, muramyldipeptide (MDP), production of proinflammatory cytokines was enhanced. Moreover, MDP-induced production of proinflammatory cytokines was inhibited in a different manner by mitogen-activated protein kinase inhibitors and phosphatidylinositol 3-kinase inhibitor. Furthermore, MDP enhanced CXCL10 and CXCL11 productions by tumor necrosis factor-alpha (TNF-alpha)- or interferon-gamma (IFN-gamma)-stimulated HGFs, although MDP alone did not induce these chemokines. TNF-alpha and IFN-gamma increased NOD2 expression in HGFs. In addition, we detected NOD2 expression in mononuclear cells and HGFs in periodontally diseased tissues. CONCLUSION These findings indicate that MDP which induces production of cytokines and chemokines from HGFs is related to the pathogenesis of periodontal disease.
Collapse
Affiliation(s)
- I Hosokawa
- Department of Conservative Dentistry, Institute of Health Biosciences, The University of Tokushima Graduate School, Tokushima, Tokushima, Japan.
| | | | | | | | | | | |
Collapse
|
39
|
Hosokawa Y, Yokoyama A, Yokoyama T, Wada N, Mori S, Matsui T, Mizukami Y, Maesato H, Maruyama K. [Relationship between drinking, smoking, and dietary habits and the body mass index of Japanese alcoholic men]. Nihon Arukoru Yakubutsu Igakkai Zasshi 2010; 45:25-37. [PMID: 20387541] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/29/2023]
Abstract
Malnutrition and emaciation in alcoholics is associated with various alcoholism-related diseases, including Wernicke's encephalopathy, aero-digestive tract cancer, and serious metabolic disorders. We used a self-administered questionnaire survey for structured dietary habit screening to evaluate the dietary profiles of 467 Japanese alcoholic men aged 40 years or over and their relationship to body mass index (BMI). Their average daily ethanol consumption was 119 +/- 65 g (845 +/- 463 kcal). The survey showed that 50.5% of the subjects consumed three meals a day; 32.8%, two meals; 12.2%, one meal; and 4.5% rarely ate. The meals mainly consisted of carbohydrates and protein, with few vegetables. Daily alcohol consumption was inversely correlated with the frequency of meals, drinking milk, and consuming confectionery. The subjects who lived with their family (72.8%) consumed more meals than the subjects liv- ing alone. After excluding 22 subjects with leg edema or ascites, the average BMI was 21.3 +/- 3.2. The group with the lowest BMI values (<18.5) accounted for 19.3% of the subjects, and those with the highest BMI values (> or = 25) accounted for 11.5%. A multivariate stepwise logistic analysis showed that BMI increased 0.15 per 22 g ethanol consumed daily and decreased 0.03 per + 10 cigarettes smoked daily, 0.43 per decrease by one in daily frequency of meals, and 0.54 per category (daily, occasionally, rarely, seldom) of milk consumption. The likelihood of a low BMI <18.5 was significantly and independently associated with smoking [OR (95%CI) =1.24 (1.02-1.51) per +10 cigarettes] and with intake of seafood [0.62 (0.41-0.94) per +1 category], milk [1.52 (1.16-2.00) per +1 category] and green and yellow vegetables [1.52 (1.05-2.21) per +1 category]. Intervention in regard to diet as well as drinking is important to preventing malnutrition and emaciation in alcoholics.
Collapse
Affiliation(s)
- Yuko Hosokawa
- National Hospital Organization Kurihama Alcoholism Center, Yokosuka, Kanagawa, 246-0841, Japan
| | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Abstract
We have reported that CXCL16, a recently discovered transmembrane chemokine, is expressed in human gingival fibroblasts (HGF). However, it is not known whether HGF express CXCR6, the receptor for CXCL16, or CXCL16 affects HGF biology. We have shown that HGF expressed CXCR6 by reverse transcription-polymerase chain reaction and flow cytometric analysis. Moreover, we elucidated that tumour necrosis factor (TNF)-alpha and cytosine-guanine dinucleotide (CpG) DNA (Toll-like receptor-9 ligand) treatment enhanced CXCR6 expression by HGF. Interleukin (IL)-4, IL-13 and CpG DNA up-regulated CXCR6 expression by TNF-alpha-stimulated HGF. On the other hand, IL-1beta and interferon-gamma inhibited CXCR6 expression on TNF-alpha-treated HGF. CXCL16 treatment induced HGF proliferation and phosphorylation of extracellular regulated kinase (ERK) and protein kinase B (AKT) in HGF. In conclusion, HGF expressed CXCR6 functionally, because CXCL16 induced HGF proliferation and ERK and AKT phosphorylation in HGF. These results indicate that CXCL16 may play an important role in the pathogenesis and remodelling in periodontally diseased tissues.
Collapse
Affiliation(s)
- Y Hosokawa
- Departments of Conservative Dentistry and Institute of Health Biosciences, The University of Tokushima Graduate School, Tokushima, Tokushima, Japan.
| | | | | | | | | |
Collapse
|
41
|
Ishihara Y, Hagiwara K, Zen K, Huqun, Hosokawa Y, Natsuhara A. A case of pulmonary alveolar microlithiasis with an intragenetic deletion in SLC34A2 detected by a genome-wide SNP study. Thorax 2009; 64:365-7. [PMID: 19329736 DOI: 10.1136/thx.2008.102996] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
A case of pulmonary alveolar microlithiasis occurring in an inbred family is presented. A genome-wide analysis of the patient's genomic DNA using a high-density single nucleotide polymorphism (SNP) array revealed a small intragenetic mutation at SLC34A2. The results suggest that the high-density SNP array has the power to identify a recessive disease gene(s) even in the analysis of only a single inbred patient.
Collapse
Affiliation(s)
- Y Ishihara
- Department of Respiratory Medicine, Omihachiman Community Medical Center, Omihachiman, Japan
| | | | | | | | | | | |
Collapse
|
42
|
Hosokawa Y, Hosokawa I, Ozaki K, Nakae H, Matsuo T. Cytokines differentially regulate CXCL10 production by interferon-γ-stimulated or tumor necrosis factor-α-stimulated human gingival fibroblasts. J Periodontal Res 2009; 44:225-31. [DOI: 10.1111/j.1600-0765.2008.01124.x] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
|
43
|
Hosokawa Y, Hosokawa I, Ozaki K, Nakae H, Matsuo T. CC chemokine ligand 17 in periodontal diseases: expression in diseased tissues and production by human gingival fibroblasts. J Periodontal Res 2008; 43:471-7. [PMID: 18557811 DOI: 10.1111/j.1600-0765.2007.01080.x] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
BACKGROUND AND OBJECTIVE It has been reported that T helper 2 (Th2) cells are related to exacerbation of periodontal disease. However, it is uncertain how the migration of Th2 cells is controlled. In this study, we examined the expression of CC chemokine ligand 17 (CCL17), which is a Th2 chemokine, in periodontal tissues. Moreover, we investigated the effects of cytokines and toll-like receptor (TLR) ligands on the production of CCL17 by human gingival fibroblasts (HGFs). MATERIAL AND METHODS We used immunohistochemistry and reverse transcriptase-polymerase chain reaction (RT-PCR) to detect CCL17 in periodontal tissues. HGFs were exposed to cytokines and TLR ligands. Expression of CCL17 was examined by RT-PCR and enzyme-linked immunosorbent assay. We used signal transduction inhibitors in some experiments. RESULTS Both CCL17 and its receptor, CC chemokine receptor 4 (CCR4), were expressed in diseased periodontal tissues. A combination of tumour necrosis factor alpha (TNF-alpha) and interleukin (IL)-4/IL-13 increased CCL17 expression. Moreover, treatment of HGFs with a low dose of interferon-gamma (IFN-gamma) in combination with TNF-alpha and IL-4 or IL-13 had synergistic effects on the production of CCL17, whereas a high dose of IFN-gamma inhibited CCL17 production. Furthermore, Escherichia coli (E. coli) lipopolysaccharide (TLR4 ligand) and Pam3CSK4 (TLR2 ligand) inhibited CCL17 production by TNF-alpha + IL-4-stimulated HGFs, while CpG DNA (TLR9 ligand) enhanced TNF-alpha + IL-4 induced-CCL17 production by HGFs. Furthermore, a c-Jun NH2 terminal kinase (JNK) inhibitor, a phosphatidylinositol-3-kinase (PI3K) inhibitor and a nuclear factor kappa B (NF-kappa B) inhibitor inhibited CCL17 production by HGFs. CONCLUSION These results suggest that the CCL17 produced by HGFs may be involved in the migration of Th2 cells into inflamed tissues, and provide evidence that CCL17 production is controlled by cytokines and TLR ligands in periodontal disease.
Collapse
Affiliation(s)
- Y Hosokawa
- Department of Conservative Dentistry, Institute of Health Biosciences, The University of Tokushima Graduate School, Tokushima, Japan.
| | | | | | | | | |
Collapse
|
44
|
Hosokawa Y, Kashii M, Yoshikawa H, Adachi H, Mori Y, Masuhara H. Femtosecond laser etching of protein crystal to process and to isolate the single crystal. Acta Crystallogr A 2008. [DOI: 10.1107/s0108767308099169] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
45
|
Hosokawa I, Hosokawa Y, Ozaki K, Nakae H, Matsuo T. Adrenomedullin suppresses tumour necrosis factor alpha-induced CXC chemokine ligand 10 production by human gingival fibroblasts. Clin Exp Immunol 2008; 152:568-75. [PMID: 18435806 DOI: 10.1111/j.1365-2249.2008.03647.x] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
Abstract
Periodontal disease is an inflammatory disorder characterized by the involvement of chemokines that are important for the recruitment of leucocytes. Several cytokines, including tumour necrosis factor alpha (TNF-alpha), are involved in regulating levels of chemokines in periodontal disease. CXC chemokine ligand 10 (CXCL10) is a chemokine related to the migration of T helper 1 cells. In this study, we examined CXCL10 expression in human gingival fibroblasts (HGFs). Moreover, we investigated the effects of adrenomedullin (AM), which is a multi-functional regulatory peptide, on the production of CXCL10 by HGFs. We revealed that TNF-alpha stimulation induced CXCL10 production by HGFs. HGFs expressed AM and AM receptors, calcitonin-receptor-like receptor (CRLR) and receptor-activity-modifying protein (RAMP) 2, mRNAs constitutively. AM treatment supressed CXCL10 production by TNF-alpha-stimulated HGFs. Moreover, we elucidated that AM produced by HGFs inhibited CXCL10 production by HGFs, because AM antagonist enhanced CXCL10 production by HGFs. TNF-alpha treatment enhanced CRLR and RAMP2 mRNA expression in HGFs. Furthermore, AM is expressed in human periodontal tissues, including both inflamed and clinically healthy tissues. These results suggest that the CXCL10 produced by HGFs may be involved in the migration of leucocytes into inflamed tissues and related to exacerbation of periodontal disease. AM might be a therapeutic target of periodontal disease, because AM can inhibit CXCL10 production by HGFs.
Collapse
Affiliation(s)
- I Hosokawa
- Department of Conservative Dentistry, Institute of Health Biosciences, The University of Tokushima Graduate School, Tokushima, Japan.
| | | | | | | | | |
Collapse
|
46
|
Hosokawa Y, Hosokawa I, Ozaki K, Nakae H, Matsuo T. CXC chemokine ligand 16 in periodontal diseases: expression in diseased tissues and production by cytokine-stimulated human gingival fibroblasts. Clin Exp Immunol 2007; 149:146-54. [PMID: 17459077 PMCID: PMC1942022 DOI: 10.1111/j.1365-2249.2007.03398.x] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
Abstract
Periodontal disease is an inflammatory disorder characterized by the involvement of chemokines that are important for the recruitment of leucocytes. Several cytokines are involved in regulating levels of chemokines in periodontal disease. CXCL16 is a chemokine related to the migration of T helper 1 (Th1) cells and natural killer (NK) cells. In this study, we examined its expression in periodontal tissues. Moreover, we investigated the effects of cytokines on the production of CXCL16 by human gingival fibroblast (HGF). Reverse transcription-polymerase chain reaction (RT-PCR) analysis and immunohistochemistry revealed that CXCL16 and its receptor, CXCR6, were expressed at the mRNA and protein levels in diseased tissues. Proinflammatory cytokines [interleukin (IL)-1beta, tumour necrosis factor (TNF)-alpha and interferon (IFN)-gamma] increased the mRNA expression and release of CXCL16 in a dose-dependent manner. Moreover, treatment of HGFs with IFN-gamma in combination with IL-1beta had a synergistic effect on the production of CXCL16. On the other hand, IL-4 and IL-13 inhibited the IL-1beta-induced CXCL16 production by HGFs. Inhibitors of A disintegrin and metalloprotease (ADAM)10 and ADAM17, a recently identified protease of CXCL16, reduced the amount of CXCL16 released from HGFs. These results suggest that the CXCL16 produced by HGFs may be involved in the migration of leucocytes into inflamed tissues, and provide evidence that CXCL16 production is controlled by cytokines in periodontal disease.
Collapse
MESH Headings
- Aged
- Cells, Cultured
- Chemokine CXCL16
- Chemokines, CXC/biosynthesis
- Chemokines, CXC/genetics
- Chronic Disease
- Cytokines/immunology
- Female
- Fibroblasts/immunology
- Gene Expression
- Gingiva/immunology
- Humans
- Interferon-gamma/immunology
- Interleukin-13/immunology
- Interleukin-1beta/immunology
- Interleukin-4/immunology
- Male
- Metalloproteases/antagonists & inhibitors
- Middle Aged
- Mitogen-Activated Protein Kinases/immunology
- Periodontitis/immunology
- RNA, Messenger/genetics
- Receptors, CXCR6
- Receptors, Chemokine/biosynthesis
- Receptors, Chemokine/genetics
- Receptors, Scavenger/biosynthesis
- Receptors, Scavenger/genetics
- Receptors, Virus/biosynthesis
- Receptors, Virus/genetics
- Reverse Transcriptase Polymerase Chain Reaction/methods
Collapse
Affiliation(s)
- Y Hosokawa
- Department of Conservative Dentistry, Institute of Health Biosciences, The University of Tokushima Graduate School, Tokushima, Japan.
| | | | | | | | | |
Collapse
|
47
|
Hosokawa Y, Hosokawa I, Ozaki K, Nakae H, Matsuo T. Proinflammatory effects of tumour necrosis factor-like weak inducer of apoptosis (TWEAK) on human gingival fibroblasts. Clin Exp Immunol 2007; 146:540-9. [PMID: 17100776 PMCID: PMC1810398 DOI: 10.1111/j.1365-2249.2006.03233.x] [Citation(s) in RCA: 40] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
Abstract
Tumour necrosis factor (TNF)-like weak inducer of apoptosis (TWEAK), a member of the TNF family, is a multi-functional cytokine that regulates cellular proliferation, angiogenesis, inflammation and apoptosis. In this study, we investigated TWEAK expression in periodontally diseased tissues and the effect of TWEAK on human gingival fibroblasts (HGF). Reverse transcription-polymerase chain reaction (RT-PCR) analysis and immunohistochemistry revealed that TWEAK and the TWEAK receptor, fibroblast growth factor-inducible 14 (Fn14), mRNA and protein were expressed in periodontally diseased tissues. HGF expressed Fn14 and produced interleukin (IL)-8 and vascular endothelial growth factor (VEGF) production upon TWEAK stimulation in a dose-dependent manner. The IL-8 and VEGF production induced by TWEAK was augmented synergistically by simultaneous stimulation with transforming growth factor (TGF)-beta1 or IL-1beta. IL-1beta and TGF-beta1 enhanced Fn14 expression in a dose-dependent manner. Moreover, TWEAK induced intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) expression on HGF in a dose-dependent manner. The ICAM-1 expression induced by TWEAK was augmented by TGF-beta1. On the other hand, the TWEAK-induced VCAM-1 expression was inhibited by TGF-beta1. Phosphatidylinositol 3-kinase (PI3K) and nuclear factor-kappaB (NF-kappaB) inhibitor inhibit both ICAM-1 and VCAM-1 expression induced by TWEAK. However, mitogen-activated protein kinase (MEK) and c-Jun NH2-terminal kinase (JNK) inhibitor enhanced only VCAM-1 expression on HGF. These results suggest that TWEAK may be involved in the pathophysiology of periodontal disease. Moreover, in combination with IL-1beta or TGF-beta1, TWEAK may be related to the exacerbation of periodontal disease to induce proinflammatory cytokines and adherent molecules by HGF.
Collapse
Affiliation(s)
- Y Hosokawa
- Department of Conservative Dentistry and Institute of Health Biosciences, The University of Tokushima Graduate School, Tokushima, Tokushima, Japan.
| | | | | | | | | |
Collapse
|
48
|
Hosokawa I, Hosokawa Y, Komatsuzawa H, Goncalves RB, Karimbux N, Napimoga MH, Seki M, Ouhara K, Sugai M, Taubman MA, Kawai T. Innate immune peptide LL-37 displays distinct expression pattern from beta-defensins in inflamed gingival tissue. Clin Exp Immunol 2007; 146:218-25. [PMID: 17034573 PMCID: PMC1942065 DOI: 10.1111/j.1365-2249.2006.03200.x] [Citation(s) in RCA: 83] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
Abstract
Anti-microbial peptides produced from mucosal epithelium appear to play pivotal roles in the host innate immune defence system in the oral cavity. In particular, human beta-defensins (hBDs) and the cathelicidin-type anti-microbial peptide, LL-37, were reported to kill periodontal disease-associated bacteria. In contrast to well-studied hBDs, little is known about the expression profiles of LL-37 in gingival tissue. In this study, the anti-microbial peptides expressed in gingival tissue were analysed using immunohistochemistry and enxyme-linked immunosorbent assay (ELISA). Immunohistochemistry revealed that neutrophils expressed only LL-37, but not hBD-2 or hBD-3, and that such expression was prominent in the inflammatory lesions when compared to healthy gingivae which showed very few or no LL-37 expressing neutrophils. Gingival epithelial cells (GEC), however, expressed all three examined anti-microbial peptides, irrespective of the presence or absence of inflammation. Moreover, as determined by ELISA, the concentration of LL-37 in the gingival tissue homogenates determined was correlated positively with the depth of the gingival crevice. Stimulation with periodontal bacteria in vitro induced both hBD-2 and LL-37 expressions by GEC, whereas peripheral blood neutrophils produced only LL-37 production, but not hBD-2, in response to the bacterial stimulation. These findings suggest that LL-37 displays distinct expression patterns from those of hBDs in gingival tissue.
Collapse
Affiliation(s)
- I Hosokawa
- Department of Immunology, The Forsyth Institute, Boston, Massachusetts, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Shioya Y, Suzuki T, Sato Y, Yoshikawa Y, Hosokawa Y, Fukunari K, Sugimoto Y, Watanabe T, Takenouchi N. 218 BREEDING TRIAL OF CONGENITAL HYDROCEPHALUS OF JAPANESE BLACK CATTLE USING EMBRYO TRANSFER. Reprod Fertil Dev 2007. [DOI: 10.1071/rdv19n1ab218] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
Hydrocephalus is a congenital defect of cattle. Births of Japanese Black calves with forehead doming were reported in Tohoku District from 1988 to 1989. The common finding on autopsy was the presence of excessive amounts of cerebrospinal fluid with expanding lateral ventricles without evidence of microbiologic infection. Breeding records for pedigree registration have been maintained by the Wagyu Registry Association in this area since 1960. A survey of the pedigrees suggested that an autosomal recessive gene might be responsible for the defect. The incidence of doming calves ceased by an advised mating system which excluded the suspected sires after 1990. Molecular genetics is useful for disclosing DNA sequences of a recessive gene and for detecting the carriers of the gene. This trial was conducted to produce congenital hydrocephalus calves for gene analysis using embryo transfer on a small number of the remaining cows that gave birth to affected calves over 10 years ago. One donor cow, 11 years old, was superovulated with 24 to 25 AU of FSH (Antrin; Kawasaki Mitaka K.K., Kawasaki, Japan) and inseminated with frozen semen of a suspected bull. Collected embryos were transferred on the day of the collection and the rest of them were frozen and transferred later. Superstimulation was repeated 4 times in this cow at an interval of 76-105 days during and 8-month period. A total of 4, 13, 17, and 18 embryos of good quality were collected. Eighteen fresh embryos were transferred into 7 (2 embryos each) and 4 (single embryo) recipients. Frozen embryos were transferred into 6 recipients (single embryo). Seven of 17 recipients became pregnant and gave birth to 8 calves. Three of 6 male calves born and one of 2 females showed symptoms of hydrocephalus. Clinically, 3 of the affected calves had a domed forehead and squint-eyes and were unable to stand. One calf underwent a fatal convulsion and ataxia 29 days after birth. Pathological findings of affected calves showed dilated bilateral ventricles with increased cerebrospinal fluid as typical lesions of hydrocephalus. Embryo transfer was demonstrated to be a useful tool for investigation of a potentially heritable disease. Gene scanning with microsatellite markers using the tissues from the calves and the related cattle was done. The suspected gene was found near the centromere of chromosome 3 (BTA3). It was possible to diagnose the mutant-carrier cattle using two DNA markers, INRA006 (17.0 cm) and BL41 (43.2 cm).
Collapse
|
50
|
Hosokawa Y, Matsuge S, Hayashi K, Tao Y, Nakno R, Kemmochi Y, Ishimine A, Murakami Y, Kano S. [Current problems in the diagnosis of malignant pleural mesothelioma]. Kyobu Geka 2007; 60:14-8. [PMID: 17249532] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/13/2023]
Abstract
The diagnosis of malignant pleural mesothelioma (MPM) is challenging although MPM is highly aggressive tumor. The current diagnostic gold standard is principally based on light microscopic examination of hematoxylin-eosin and immunohistochemical stains of large tissue sections. However, pathological diagnosis of MPM and classification of histological findings into 1 of the 3 subtypes (epithelial, sarcomatoid, biphasic) are difficult. We studied correlation between initial and final histological diagnosis retrospectively from the records of 21 cases with MPM from 1989 to 2005. The diagnosis of MPM was confirmed by histopathological examination of pleural tissue samples obtained by closed biopsy under computed tomography (CT) or ultrasonography-guided (5 cases), by biopsy under thoracoscopy with local anesthesia (9), by open biopsy via thoracotomy (2), and by video-assisted thoracoscopic surgery (VATS) [5] . Pleural biopsy under those diagnostic methods led to initial diagnosis of MPM in 15 of 21 cases (71.4%) . In 6 cases (28.6%) , initial diagnosis of MPM were not confirmed because of missing malignant tissue (1 case) and relatively small and sarcomatous element (5). In 2 cases examined by closed biopsy and in 3 examined by thoracoscopy under local anesthesia, initial diagnosis of MPM were not confirmed. To get the accurate diagnosis of MPM, obtaining large tissue samples in the initial examination by less invasive thoracoscopy is recommended.
Collapse
Affiliation(s)
- Y Hosokawa
- Department of Surgery, Kin-ikyo Sapporo Hospital, Sapporo, Japan
| | | | | | | | | | | | | | | | | |
Collapse
|